

Review Article

Potential Roles of Endoplasmic Reticulum Stress and Cellular Proteins Implicated in Diabetes

Sagir Mustapha ^{1,2} **Mustapha Mohammed** ^{3,4} **Ahmad Khusairi Azemi** ¹
Ismaeel Yunusa ⁵ **Aishatu Shehu** ² **Lukman Mustapha** ⁶ **Yusuf Wada** ^{7,8}
Mubarak Hussaini Ahmad ^{2,9} **Wan Amir Nizam Wan Ahmad** ¹⁰
Aida Hanum Ghulam Rasool ^{1,11} and **Siti Safiah Mokhtar** ¹

¹Department of Pharmacology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kota Bharu, Kelantan, Malaysia

²Department of Pharmacology and Therapeutics, Ahmadu Bello University Zaria, Kaduna, Nigeria

³School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Pulau Pinang, Malaysia

⁴Department of Clinical Pharmacy and Pharmacy Practice, Ahmadu Bello University Zaria, Kaduna, Nigeria

⁵Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, College of Pharmacy, Columbia, SC, USA

⁶Department of Pharmaceutical and Medicinal Chemistry, Kaduna State University, Kaduna, Nigeria

⁷Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kota Bharu, Kelantan, Malaysia

⁸Department of Zoology, Ahmadu Bello University Zaria, Kaduna, Nigeria

⁹School of Pharmacy Technician, Aminu Dabo College of Health Sciences and Technology, Kano, Nigeria

¹⁰Biomedicine Programme, School of Health Sciences, Universiti Sains Malaysia, 16150 Kota Bharu, Kelantan, Malaysia

¹¹Hospital Universiti Sains Malaysia, 16150 Kota Bharu, Kelantan, Malaysia

Correspondence should be addressed to Siti Safiah Mokhtar; safiahm@usm.my

Received 19 September 2020; Revised 28 March 2021; Accepted 5 April 2021; Published 28 April 2021

Academic Editor: Silvana Hrelia

Copyright © 2021 Sagir Mustapha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The role of the endoplasmic reticulum (ER) has evolved from protein synthesis, processing, and other secretory pathways to forming a foundation for lipid biosynthesis and other metabolic functions. Maintaining ER homeostasis is essential for normal cellular function and survival. An imbalance in the ER implied stressful conditions such as metabolic distress, which activates a protective process called unfolded protein response (UPR). This response is activated through some canonical branches of ER stress, i.e., the protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 1 α (IRE1 α), and activating transcription factor 6 (ATF6). Therefore, chronic hyperglycemia, hyperinsulinemia, increased proinflammatory cytokines, and free fatty acids (FFAs) found in diabetes (a pathophysiological link between obesity and diabetes) could lead to ER stress. However, limited data exist regarding ER stress and its association with diabetes, particularly the implicated proteins and molecular mechanisms. Thus, this review highlights the role of ER stress in relation to some proteins involved in diabetes pathogenesis and provides insight into possible pathways that could serve as novel targets for therapeutic intervention.

1. Introduction

Diabetes is a complex condition associated with a high amount of glucose in the blood resulting from an absolute or relative lack of insulin [1]. Its increasing global prevalence has been attributed mainly to the pandemic of obesity and

sedentary lifestyles [2, 3]. Obesity is a significant risk factor for the development of diabetes [4]. In turn, obesity may coexist with diabetes, a condition referred to as diabetes [5]. About 30% of obese patients are at risk of advancing into diabetes, owing to decreased tyrosine phosphorylation levels on insulin receptor substrate 1 (IRS-1) [6, 7]. Usually, the

insulin activates the insulin receptor via dimerization and transautophosphorylation, which phosphorylate the tyrosine residues site on IRS-1 and IRS-2, leading to the activation and recruitment of other cellular components needed for an insulin signaling cascade, such as phosphatidylinositol 3-kinase/protein kinase B (PI3k/Akt/eNOS).

Diabesity as a metabolic disorder that presents with hyperglycemia and hyperlipidemia, leading to endoplasmic reticulum (ER) stress and ultimately contributing to insulin resistance. The ER structure is the central station for protein synthesis and serves other metabolic functions [8]. The cellular activation of IRS-1 by insulin receptors stimulates sustained cell growth and an antiapoptotic response, whereas insulin resistance from ER stress leads to inhibition of the IRS-1 functions [9]. ER stress results in serine phosphorylation of IRS-1 via c Jun N terminal kinases (JNK), leading to insulin resistance. Insulin resistance stimulates serine/threonine kinases that phosphorylate IRS-1, thereby inhibiting its normal functions. Several studies have proposed mediators such as endothelin-1, free fatty acids (FFA), tumor necrosis alpha (TNF α), amino acids, angiotensin II (ang II), and hyperinsulinemia as catalysts for insulin resistance [10–17]. However, little is known about the relationship between ER stress and proteins such as endothelial nitric oxide synthase (eNOS), endothelium-derived endothelin-1 (ET-1), insulin receptor substrate (IRS-1 and IRS-2), nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase, and caveolin 1 (Cav-1), all of which are implicated in diabesity.

At the cellular level, a drop in glucose uptake as a result of a decline in IRS-1 tyrosine phosphorylation and phosphatidylinositol 3-kinase (PI3k) stimulation in animal models leads to high levels of glucose in the blood, which initiate ER stress [6, 18]. In the pathogenesis of diabesity, hyperglycemia and hyperinsulinemia cause more glucose to be oxidized via the pentose phosphate pathway (PPP), creating a massive NADPH electron donor to fuel superoxide anion production [19]. A large amount of superoxide anion in the cell may lead to ER stress [20]. ER stress, in turn, may affect normal physiological conditions in the cell.

Several mechanisms of diabesity in relation to ER stress have been reported. It is believed that ER stress leads to abnormal cell signaling in response to insulin, causing insulin resistance, as seen in diabesity. To date, no study has identified cellular proteins implicated in ER stress signaling pathways in diabesity. Therefore, this review is aimed at highlighting the roles of ER stress and its relationship with some cellular proteins implicated in diabesity, such as eNOS, ET-1, IRS-1 and IRS-2, NAD(P)H oxidase, and Cav-1.

2. The Endoplasmic Reticulum (ER)

The ER was first discovered in cultured mice fibroblast and later established in all eukaryotic cells, except matured red blood cells [21]. Borgese et al. [22] later reported the existence of smooth ER and rough ER. Shibata et al. [23] proposed a new concept that grouped ER into a membrane structure. The ER's architectural nature is organized into a nuclear envelope, sheet-like cisternae, and a polygonal array of tubules connected by three-way junctions [23]. The ER is

the central station for protein synthesis, protein secretions, and other cellular metabolic functions [8]. It also serves as a signaling pathway between the cell cytosol and the nucleus [24]. Factors such as an oxidative environment, folding enzymes, chaperones, and a high amount of Ca²⁺ are needed for effective ER function [25]. Almanza et al. [26] reported that ER has advanced from a major role in protein synthesis to a foundation for metabolic functions. It is believed that the level of glucose in the body has a profound effect on ER stability, leading to a pathway activation called unfolded protein response (UPR). UPR acts via coping mechanisms such as enlarging the ER's size, among other responses, for cell survival [27]. When these coping mechanisms fail, a condition called ER stress results [28].

The mitochondria-associated ER membrane (MAM) is a structure that exists between the ER and mitochondria. The MAM plays a crucial role in Ca²⁺ stability [29]. Endolysosomal system circulation also helps maintain cellular homeostasis since it controls the internalization and processing of a broad range of integral proteins, such as signaling receptors, adhesion molecules, nutrient transporters, and lysosomal hydrolase receptors [30]. Morphology-1 comprises new mitochondria-vacuole membrane contact sites (MCSs) responsible for tethering protein for ER-vacuole/lysosome, which precisely locates nuclear ER-vacuole junctions. Mitochondrial-mediated interaction between ER and endolysosomal system circulation and morphology-1 complexes suggests ER participation in autophagy [31]. The omegasome (a structure in the ER) interacts with the phagophore (a tiny, nanomembrane sac-like structure), resulting in the formation of autophagosomes, which play an essential role in the cell degradation pathway [32, 33]. Thus, it is imperative to understand the in-depth relationship between ER and other cellular organelles, such as mitochondria, lysosomes, Golgi body, peroxisomes, endosomes, and plasma membrane, to gain insights that may pave the way to optimal management of diabesity.

3. The ER Stress Mechanism

ER homeostasis plays a critical role in cellular function and growth, while ER stress causes a physiopathological process that can lead to diabetes, obesity, cancer, and diabesity [34–36]. ER stress sets in when the ER condition is unstable because of unfolded proteins that exceed its handling ability [34]. ER stress in human tissues has also been shown to be caused by hyperglycemia and hyperinsulinemia [37]. Hyperglycemia and hyperinsulinemia are associated with enhanced protein production and posttranslational protein modifications such as ubiquitinations, indicating an amplified misfolded or unfolded protein, a significant source of ER stress [37, 38]. Prior to ER stress, cells primarily adjust to misfolded protein overload in the ER lumen by increasing the amount of molecular chaperones, called binding immunoglobulin protein (BiP) [39]. BiP is a molecular chaperone found in the ER lumen only. In the absence of stress, BiP is primarily known to bind to the three kinds of ER arm sensors, namely, inositol-requiring kinase 1 (IRE1), PKR-like ER kinase (PERK), and activating transcription factor 6 (ATF6) transmembrane, thereby avoiding ER stress initiation [34, 40],

and BiP is known to be sensitive to glucose concentration in the cell [41, 42]. The literature contains no clear indication of which of the three above-named ER arm sensors is activated first. However, Hu et al. [43] reported that the first pathway activated among the three ER protein membranes is PERK. When ER stress has been initiated due to unfolded protein, the three-arm sensors are usually all affected [27]. The molecular mechanisms underlying ER stress are not clearly understood in association with diabetes.

IRE1 is expressed in two forms, either IRE1 β or IRE1 α . IRE1 β is mainly found in the epithelium of the gastrointestinal tract [44], while IRE1 α is pervasively present in all cells but particularly prolific in the eukaryotic cells and is exceptionally well preserved [27]. Usually, IRE1 binds to BiP in the ER lumen to form a nonactive complex. A high concentration of misfolded proteins in the luminal area of ER leads to kinase activities that cause IRE1 α activation to elicit its RNase activity during ER stress. IRE1 α , type 1 ER transmembrane protein, undergoes kinase/endoribonuclease, oligomerization, and autophosphorylation. IRE-1 has a novel endoribonuclease function that contributes to its substrate, the 26-nucleotide sequence X box-binding protein 1 (XBP1) mRNA, being excised and spliced. Spliced XBP1 results in the overexpression of genes responsible for unfolded protein degradation and ER protein translocation, folding, and secretion [45, 46]. Also, spliced XBP1 translocates to the promoter region of the ER stress-mediated response and binds to it, enabling it to control many genes associated with UPR that are crucial in stimulating the degradation of dysregulated cells [47, 48]. IRE1 α can also break precursor microRNAs (miRNAs) or a small collection of mRNAs in a process called regulated IRE1-dependent decay (RIDD). RIDD may lead to the degradation of mRNA and prevent protein load. RIDD has been found to control multiple signaling pathways on the ER, including selectively cleaving mRNAs [49, 50]. Recently, IRE1 α was discovered to form complexes with the machinery of translocation and translational parts, such as transfer RNA, signal recognition particle RNA, and ribosomal RNA. However, the biological essence of these interactions remains to be elucidated. IRE1 α interactions with RNA are unknown, but its biological activities remain to be seen. The crosstalk between IRE1 α and some noncanonical mediators such as mitogen-activated protein kinase (MAPK) and macroautophagy is of great interest. Also, IRE-1 interacts with tumor necrosis factor α receptor-associated factor 2 (TRAF2) to activate inflammatory response-related protein kinases and cellular apoptosis, such as apoptosis signal-regulating kinase 1 (ASK1) and triggers the activation of JNK [28]. JNK is activated in the mitochondria and facilitates the phosphorylation of proapoptotic proteins, leading to the initiation of cell death and inhibiting antiapoptotic proteins [51].

There are three physiological variants of IRE1 α , i.e., monomeric, dimeric, and multimeric forms. The monomeric form is bound to the BiP at the N-terminal luminal domain (NLD) to form an inactive complex, while the dimeric and multimeric are active forms. It is crucial to understand IRE1 from a broader perspective as an ER stress arm-sensor, not limited to mechanisms and structure.

When PERK is dissociated from BiP, it will undergo dimerization and autophosphorylation. The phosphorylated PERK stimulates and phosphorylates eukaryotic initiation factor 2 α (eIF2 α) [27]. eIF2 α leads to a downstream signaling cascade that attenuates protein production and transcriptional factors such as activation transcription factor-4 (ATF-4) and CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP). These transcriptions promote genes responsible for survival [52, 53]. The downstream signaling cascade is a reversible process that limits the entry of newly formed proteins into the ER lumen. It also promotes maintaining ER homeostasis and proper protein folding, as well as assembling. PERK also takes part in tethering the association between the ER and mitochondria, which may involve ROS production [54]. The initial activation of activating transcription factor-4 (ATF-4) is for cell survival during UPR. The ATF-4 is involved in negative feedback to dephosphorylate eIF2 α via protein phosphatase 1 (PP1) regulatory subunit growth arrest and DNA damage-inducible protein (GADD34). The GADD34 and the constitutive repressor of eIF2 α phosphorylation (CReP) are essential agents in restoring normal protein production via PERK, as the cell has been relieved of ER stress. ATF-4 also takes part in the dephosphorylation of eIF2 via a negative feedback mechanism as protein production is being restored (using protein phosphatase 1 as a subunit of GADD34).

During chronic ER stress, PERK activates the downstream signaling of eIF2/ATF-4/CHOP, which alters the translational and transcriptional process, resulting in enhanced activation of nuclear factor-kappa B (NF- κ B) [55]. Therefore, activation of NF- κ B will lead to the elimination of the damaged cells. Cells that are deficient in PERK or phosphorylated eIF2 α may increase the accumulation of misfolded or unfolded proteins in the ER lumen [25]. Several studies have demonstrated the relationship between ER stress and PERK. Elouil et al. [56] and Hou et al. [57] reported that prolonged hyperglycemia for more than 18 hours leads to PERK activation, thereby causing ER stress. However, Gomez et al. [58] reported that exposure to lower glucose levels and a shorter time is likely to facilitate PERK activation, resulting in the phosphorylation of eIF2 α .

The ATF6p90, as the last arm sensor of ER stress, is a transmembrane transcriptional factor with both C terminal and N terminal domains [59]. It has two forms of mammalian genes, namely, ATF6 α and ATF6 β [60]. During ER stress, there is an upsurge in the aggregation of misfolded proteins in the ER's lumen that leads to BiP detachment from ATF-6p90. When ATF6p90 reaches the Golgi apparatus, it is then cleaved via the protease site 1 and protease site 2 to discharge ATF6p50 containing basic leucine zipper, transcription activation domain, nuclear localization signals, and DNA binding domain. The nucleus receives this processed ATF-6p50 from the Golgi apparatus and induces the gene expression [61, 62]. Although ATF6p50 and XBP1s are parallel to each other, they intersect in their downstream signaling cascade to control gene transcription, such as endoplasmic reticulum-associated protein degradation (ERAD), enhanced protein folding, secretion and maturation, and ER chaperones [63, 64]. When the UPR fails to free the cell from ER

stress, the cell will prepare for cell death by CHOP activation via ATF-6. For example, studies conducted by Wu et al. [65] and Yamamoto et al. [36] show that mice using ATF-6 inducers without ATF-6 had amplified ER stress. Also, it is worth noting that there are other basic leucine zipper transcription factors in the ER, such as cyclic adenosine monophosphate- (cAMP-) responsive element-binding protein H (CREB-H), cAMP-responsive element-binding protein-4 (CREB4), also known as Luman, and old astrocyte specifically induced substance (OASIS), which may be engaged during ER stress signaling [66]. This indicates how complex the ER stress signaling cascade is in association with other non-canonical pathways.

Therefore, understanding the complex mechanisms involving the three ER arm sensors and their interconnections is necessary if diseases such as diabetes are managed. It is crucial to establish which of the arm proteins is activated first, at what point, and the interswitch during ER stress. It is also essential to identify the impact of noncanonical pathways in diabetes.

4. Diabetes

Diabetes or obese diabetes occurs in subjects with obesity, who then develop type 2 diabetes [35]. Sims et al. [67] were the first investigators to coin the word diabetes in 1973, recognizing the cooccurrence of diabetes and obesity. The prevalence of obesity is increasing globally, as is that of type 2 diabetes. Diabetes exhibits common features in diabetes and obesity (such as adipose tissue, skeletal muscle, vascular, endothelial cell, and liver dysfunctions). Diabetes is associated with the disruption of metabolic cell signaling pathways and attenuated insulin signaling, that is, insulin dysfunction, which raises the risk of type 2 diabetes [68]. Diabetes, type 2 diabetes, and obesity alter many metabolic cascades, such as mitogen-activated protein kinase (MAPK), mammalian target of rapamycin (mTOR), and phosphoinositide-3-kinase/protein kinase B (PI3K/Akt), which has a systemic effect [69]. The attenuation of the above signaling cascade presents a condition called insulin dysfunction. Insulin dysfunction is also one of the main symptoms of obesity and diabetes. ER stress has been identified as one of the molecular mechanisms linked to insulin dysfunction [70]. ER stress has been seen in patients with diabetes, obesity, and type 2 diabetes, with significant effects on skeletal muscles, the fetoplacental vascular endothelium, visceral adipose tissue, and the liver. ER stress initiation via IRE-1 α mediates stimulation of JNK and inhibitory kappa B kinase (IKK) [71]. The activation of JNK mediates the impairment of insulin via the serine phosphorylation of insulin receptor substrate (IRS) [72]. The end product of these metabolic cascades is called diabetes. The relationship between impaired insulin, ER stress, and diabetes is shown in Figure 1.

5. Cellular Proteins Implicated in Diabetes

Cellular proteins are macromolecules that are essential in many cellular functions in a living system. These proteins are involved in daily cellular activities, regulations, opera-

tions, and structures, one function being to help maintain the hemodynamic and structural integrity of a cell. Some cellular proteins affected by the physiopathology of diabetes include eNOS, ET-1, IRS-1, NADPH oxidase, and Cav-1. eNOS, as a cellular protein or enzyme, is essential for the production of nitric oxide (NO), while ET-1 is responsible for the vasoconstriction effect on the blood vessels. Also, IRS-1 plays an essential role in the insulin signaling pathways; meanwhile, NAD(P)H oxidase is responsible for producing reactive oxygen species that participate in the protein folding process. Cav-1 is the site for diverse signaling mechanisms, which could be interrupted due to ER stress.

6. ER Stress and Endothelial Nitric Oxide Synthase (eNOS)

For decades, the endothelium was viewed first as an inert barrier that coats all blood vessels along the vasculature. Extensive studies led to a breakthrough in understanding its dynamic roles and its function in sustaining cardiovascular stability. The endothelium is currently identified as a fundamental unit of the endocrine organ that possesses various metabolic, immunological, and secretory features rather than as an inert barrier. The endothelium begins from the heart and runs through the blood vessel walls in the body. Also, structurally endothelium-derived relaxing factor (EDRF), in the form of nitric oxide (NO) or a nitrogen oxide-containing compound, plays a crucial role in maintaining homeostasis in the vasculature and producing an antithrombotic effect. The total formation of NO in mice has been documented to be approximately 0.2 mmol/kg/day, of which nearly 70% is obtained from eNOS [73]. The NO synthesis rate in humans is approximately 0.9 μ mol/kg/h, while in Wistar rats, it is about 0.33–0.85 μ mol/kg/h [74–77]. NO generation is achieved through endothelial nitric oxide synthase (eNOS) [78].

eNOS consists of two similar subunits that exist as a homodimer structurally. The eNOS subunits contain the oxygenase domain and the reductase domain. The reductase domain has a binding site for the following cofactors: flavin mononucleotide (FMN), NADPH, and flavin adenine dinucleotide (FAD). In contrast, the oxygenase domain has binding sites for L-arginine, heme, and tetrahydrobiopterin (BH₄). The calmodulin (CaM) binding domain serves to link the oxygenase domain and the reductase domain. The CaM binding domain plays a potential role in both functions and in maintaining the structure of eNOS. For eNOS to function under normal physiological conditions, the reductase domain and the oxygenase domain must come together in a homodimer in the presence of the cofactors (CaM, BH₄, and heme) [79, 80]. The activation of eNOS could be calcium-dependent or calcium-independent (G protein, shear stress, and cyclic strain) [81–83].

The eNOS mechanisms are highly complex and can be divided into protein and genetic levels. The eNOS protein mechanism involves phosphorylation by Akt, CaM complex formation, transfer of electrons from the reductase domain to the oxygenase domain, and the translocation of eNOS. In the resting state, eNOS is attached to Cav-1 at the cell




FIGURE 1: Relationship between insulin impairment, ER stress, and diabetes. JNK: c-Jun N-terminal kinase; NF- κ B: nuclear factor-kappa B; IR: insulin resistance; NO: nitric oxide; Akt: protein kinase B; MAPK: mitogen activated protein kinase; mTOR: mammalian target of rapamycin; PI3K: phosphoinositide-3-kinase; eNOS: endothelial nitric oxide synthase; IRS-1 and 2: insulin receptor substrate; ER stress: endoplasmic reticulum stress; IL6: interleukin-6; IL-4: interleukin-4; TNF α : tumour necrosis factor α ; ROS: reactive oxygen species; BH $_4$: tetrahydrobiopterin; NAD(P)H: nicotinamide adenine dinucleotide phosphate oxidase; Cav-1: caveolin-1; Et-1: endothelin-1.

membrane. Cav-1 is bound to both the reductase domain and the oxygenase domain to prevent the heme iron from being in contact with eNOS, hindering electron movement from the reductase domain. It has been reported that eNOS and Cav-1 interact with two new proteins, i.e., eNOS traffic inducer (NOSTRIN) and eNOS interacting protein (NOSIP), to form a ternary complex. Such a complex triggers eNOS relocation from the cell membrane and significantly decreases eNOS activity [84, 85]. In response to various agonists such as shear pressure and bradykinin or acetylcholine (Ach), intracellular Ca $^{2+}$ concentrations may increase. This causes Cav-1 to dissociate from eNOS, enabling CaM and heat shock protein 90 (hsp90) to bind to eNOS [86]. The binding of CaM to eNOS allows Akt to phosphorylate eNOS in both human and animal models at serine 1177 and serine 1179 , respectively, while at the same time, Akt causes dephosphorylation at the inhibitory site of eNOS at threonine 495 (Thr 495) [83, 87]. When Akt phosphorylates eNOS at serine, NO production starts with amino acid L-arginine oxidation to generate NO and L-citrulline [88]. Akt often exists inactively in the cytoplasm; its activation and phosphorylation of eNOS are caused by translocation of Akt to the cell membrane [89]. The phosphatidylinositol-3 kinase pathways (IRS/PI3K/Akt) directly regulate this, Akt being recruited to the cell membrane and phosphorylated by PI3K [90]. It is important to note that increased intracellular Ca $^{2+}$ concentration is needed for sufficient eNOS activation and NO bioavailability. This process is known as calcium-dependent eNOS phosphorylation. Bradykinin and 5-hydroxytryptamine (5-HT) interact with plasma membrane receptors, resulting in increased cytoplasmic Ca $^{2+}$ and CaM activation [91].

The expression and stability of eNOS genes are linked to eNOS behavior at the genetic level. A substantial number of

binding sites for transcription factors are included in the eNOS promoter region, comprising the endothelin family, neurofibromin 1 (NF-1), activator protein-1 (AP-1), nuclear factor- κ B (NF- κ B), and activator protein-2 (AP-2). These complexes in the transcription factor can control eNOS expression. It is now known that various factors affect eNOS expression, among them are estrogen, exercise, and hypoxia [92–94].

In pathological conditions such as diabetes, there is reduced bioavailability of BH $_4$ and NADPH [95]. NAD(P)H oxidase is more active in diabetes than in normal physiological conditions, owing to hyperlipidemia, cytokines, ang II, and hyperglycemia [96]. The increased NAD(P)H oxidase activity results in the oxidation of BH $_4$, a cofactor of eNOS, and the production of reactive oxygen species (ROS) [97]. ROS production by NAD(P)H oxidase may amplify ER stress [98]. The association between eNOS and ER stress may be due to chronic hyperglycemia, which increases oxidative stress [99]. ER stress signaling and increased NAD(P)H oxidase may be the initiators of eNOS uncoupling because of decreased NO bioavailability and amplified ROS generation [100, 101], as depicted in Figure 2. Hyperglycemia wholly or partially leads to increased oxidative stress, resulting in endothelial dysfunction [102]. Also, eNOS expression decreases when protein kinase C (PKC) is activated because of chronic hyperglycemia, which similarly in diabetes enhances the stimulation of NAD(P)H oxidase [103–105].

The dysfunction of endothelial cells occurs via eNOS uncoupling and increased ER stress. A study by Mokhtar et al. [106] reported decreased eNOS expression in the diabetic rat model; such a reduction could likely be due to ER stress. The high amount of glucose in the blood prompts the endothelial cell to initiate ER stress [107], which may be due to diabetes. First and foremost, it must be noted that




FIGURE 2: eNOS, NADPH, and ER stress consequential generation of NO and superoxide anion from coupled and uncoupled NOS. eNOS requires substrates such as oxygen, BH₄ cofactors, L-arginine, NADPH, FMN, and heme. In the physiological circumstances, the availability of BH₄ is sustained by guanosine triphosphate (GTP), such that the rate-limiting step is catalyzed by GTP cyclohydrolase I (GTPCH). The enzyme dihydrofolate reductase (DHFR) mediates the reprocessing of BH₂ to produce BH₄ as the primary nonenzymatic oxidation. eNOS uncoupling leads to the generation of superoxide anion. The superoxide anion produced results in decreased bioavailability of BH₄. As such, superoxide anions generated owing to uncoupled eNOS reacts with NO to produce ONOO⁻, a highly reactive anion that quickly oxidizes BH₄. Furthermore, self-propagating oxidative stress can stabilize eNOS uncoupling. Other demonstrated mechanisms that enhance the uncoupling of eNOS include high concentrations of endogenous NO synthase inhibitors, increased levels of oxidized glutathione relative to decreased glutathione, and reduced availability of arginine. BH₂: dihydrobiopterin; BH₄: tetrahydrobiopterin; DHFR: dihydrofolate reductase; OS: oxidative stress; NO: nitric oxide; eNOS: endothelial nitric oxide synthase; NADPH: nicotinamide adenine dinucleotide phosphate; ONOO⁻: peroxynitrite; L-NMMA: NG-monomethyl-L-arginine; ADMA: asymmetric dimethylarginine; GSSG: oxidized glutathione; GSH: reduced glutathione.

ER stress contributes to insulin dysfunction, which leads to an enhanced progression of hyperglycemia in the blood vessels. The result of insulin dysfunction affects insulin signaling pathways (IRS/PI3K/Akt), which decreases the availability of Akt and in turn results in a small amount of NO because of eNOS uncoupling. Also, chronic hyperglycemia causes eNOS uncoupling, leading to endothelial dysfunction via many unidentified pathways. Thus, identifying these pathways can serve as a first step in preventing or reducing morbidity and mortality associated with diabetes.

7. ER Stress and Endothelium-Derived Endothelin-1 (ET-1)

Endothelin consists of three family isoforms (ET-1, ET-2, and ET-3), of which ET-1 is the most widely distributed member of the family [108]. ET-1 is recognized as an endothelium-derived contracting factor (EDCF) [109]. It is produced by many types of cells and contains 21-amino acid peptides [110]. ET-1 has a half-life of around 1 min in a healthy individual [111]. It is involved in the pathogenesis of many diseases, including type 1 diabetes, diabetes, hypertension, fibrosis, and atherosclerosis [112]. Endothelin receptors (ETRs) are G protein-coupled receptors comprising endothelin A receptor (ET_AR) and endothelin B receptor

(ET_BR), which demonstrate opposite actions in cardiovascular conditions [113]. ET_AR is found on the smooth muscle cells and mediates vasoconstriction. It also induces proliferative responses linked with type 1 diabetes, diabetes, hypertension, and other related cardiovascular diseases. However, ET_BR is found on the vascular endothelial cells and mediates vasodilation [112]. It plays an essential role as a clearance receptor for the ET-1 in the system. The two ETRs are implicated in the development of many diseases, including diabetes. ET-1 is known to stimulate proteins associated with many signaling pathways, such as PI3K, NFκB, MAPK, phospholipases, beta-catenin, hypoxia-inducible factor 1 alpha, protein kinase C, RHO, and protein kinase A [114].

Vasoconstrictors enhance the production of ET-1, which results in increased vasoreactivity in response to serotonin, norepinephrine (NE), and ang II [115]. Typically, insulin binds to the insulin receptor (IR) and activates the receptor via dimerization and transautophosphorylation of the tyrosine residue. IR phosphorylation leads to activation and phosphorylation of the IRS family (IRS-1 and IRS-2). The Src homology 2 domain docks on the IRS-1, bound by growth factor receptor-bound protein 2 (Grb-2) [116]. Grb-2 serves to stimulate the preassociated guanine nucleotide exchange factor Son of Sevenless (SOS). The SOS protein activates Ras-bound guanosine diphosphate (GDP) to Ras-

bound guanosine triphosphate (GTP). Ras becomes more active with GTP, which activates and phosphorylates a cytoplasmic protein called Raf (MAPKKK). The activation of Raf initiate kinase signaling by, for example, MAPKK and MAPK. An MAPK insulin signaling cascade regulates actions associated with differentiation, growth, mitogenesis, ET-1 [117, 118], plasminogen activator inhibitor type 1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin [119]. It is important to note that impairment of IRS/PI3K/Akt signaling pathways results in overexpression of ET-1, E-selectin, and VCAM-1 and decreases the bioavailability of NO owing to the overactivation of MAPK signaling pathways [119]. The consequences for the endothelial function of both insulin dysfunction and hyperinsulinemia due to diabetes are more severe than the individual effects.

The overexpression of ET-1 in the endothelium causes an amplified expression of genes responsible for lipid production in the vascular cells [120]. This could lead to an overload of misfolded and unfolded proteins in the ER lumen, resulting in ER stress. Sustained periods of cellular stress may cause a build-up of misfolded proteins in the ER lumen, exceeding its protein-folding capacity and thence leading to activation of a coping signaling mechanism known as UPR [121–123]. Enhanced levels of ET-1 are a sign of pathology in many diseases that trigger processes such as ER stress, inflammation, and oxidative stress. Physiological messengers like ROS are essential in maintaining homeostasis in vasculatures, but their increased generation may contribute to ER stress progression, leading to diabetes. A study by Mian et al. [124] demonstrated that ET-1 is overexpressed in the endothelium of mice, owing to impairment of IRS/PI3K/Akt pathways with an increase in voltage-dependent potassium channel activity. Also, ET-1 activates ET_BR, which in turn stimulates phospholipase C (PLC) and inositol 1,4,5-trisphosphate (IP3) in the ER to discharge Ca²⁺. These actions initiate ER stress in the placenta tissue [125]. ET-1 also causes the overexpression of molecular chaperones (GRP78 and GRP94) and enhanced phosphorylation of eIF2 α , ER stress indicators [125]. A study by Wang et al. [126] on mice showed an increase in ER stress biomarkers (GRP78 and CHOP). Therefore, it is suggested that ER stress is activated by ET-1 in diseases. In diabetes, ET-1 is likely a potent initiator of ER stress via a dual action by disrupting the Ca²⁺/ER balance. In some studies, it was found that ET-1 is increased in diabetic patients compared to controls [127, 128].

8. ER Stress and Inhibition of the Insulin Receptor Substrate

Nutrient overload may be implicated in the etiology of diabetes, diabetes, and insulin resistance [35, 129]. Resistance to insulin causes dyslipidemia, hyperinsulinemia, hypertension, and hyperglycemia [35]. Many factors lead to insulin resistance, including IRS-1 and IRS-2 [130–133]. Insulin signaling in physiological and pathological circumstances is modulated by the insulin receptor substrate (IRS) family. IRS has an amino and carboxyl group domain that contains the serine/threonine and tyrosine sites for phosphorylation [134]. The concentration of insulin required to activate and

phosphorylate PI3K/Akt/eNOS pathways is less than the concentration required to phosphorylate the Ras/MAPK pathway [135]. Usually, insulin activates the insulin receptor via dimerization and transautophosphorylation of the insulin receptor. This process leads to the recruitment and phosphorylation of tyrosine residues on IRS-1 and IRS-2, which activate and recruit Src homology domain proteins. The Src homology domain provides a docking site for Grb-2 and SOS [130]. Grb-2 results in the activation and recruitment of PI3K, which leads to a downstream signaling cascade of insulin. The duration or strength of these mechanisms is influenced by many factors, including the stability of the insulin isoform receptors (IRA and IRB) or postreceptor activities such as insulin signaling cascade (IRS/PI3K/Akt/eNOS) [136]. Other regulatory proteins and signaling cascades can have a negative impact on the insulin signaling pathway by heightening insulin resistance, for example, phosphatidylcholine transfer protein [137], the Lin28/Let-7 axis [138], muscle-specific mitsugumin 53/tripartite motif 72 (MG53/TRIM72) [139], Grb10 [140], and the cullin RING E3 ubiquitin ligase-7 (CRL-7) [141]. Insulin receptors can be negatively controlled by phosphatase and tensin homolog (PTEN) and tyrosine-protein phosphatase nonreceptor type 1 (PTPN-1) [142, 143].

IRS-1 and IRS-2 tyrosine phosphorylation are responsible for the insulin signaling cascade, but the serine and threonine residues are phosphorylated before, during, and after insulin activation [130, 144]. IRS-1 has about 200 serine/threonine residues, of which around 30 are known to be phosphorylated [145, 146]. Of all the serine and threonine residues, S³⁰⁷ is the most investigated because it is implicated in physiological and pathological conditions, including insulin resistance, hyperinsulinemia, obesity, and ER stress [130, 147–149]. It is essential to note that S³⁰⁷ contributes to insulin resistance, but its phosphorylation is also critical in the physiological insulin cascade [150]. In the study by Copps et al. [150], this remained the case when S³⁰⁷ was replaced with Ala³⁰⁷; it equally did not show hypersensitivity, but it did promote significant insulin resistance in the mice used [150]. Insulin resistance may worsen due to hyperinsulinemia, which then compounds the problem of serine and threonine phosphorylation on IRS-1 [151]. To date, there is no holistic understanding of insulin signaling cascade and regulatory mechanisms, the challenge in particular being the high serine and threonine residues on IRS-1.

In pathological conditions such as diabetes, multiple sites of IRS-1 containing serine and threonine may be phosphorylated by many kinases, for example, pelle-like kinase/interleukin-1 receptor-associated kinase (mPLK), lipid/inflammatory stimulated JNK, an inhibitor of nuclear factor kappaB kinase beta (IKKB), PKC, and sympathetic-activated protein-coupled receptor kinase 2 [130] and ER stress [152]. ER stress is part of the physiopathological processes that feature in beta cell failure, leading to the disease progression.

ER stress is believed to cause insulin resistance via the activation of JNK, which leads to the inhibition of IRS-1 by phosphorylating the serine residue [153]. The activated JNK causes insulin resistance in obesity and possibly in

diabetes in four ways: inhibition of IRS-1 phosphorylation directly, the inhibition of PPAR α -FGF21 axis hormones, induction of cytokines and inflammation, and enhanced metabolic and adipogenesis efficiency [153, 154]. Also, Liang et al. [152] have shown that ER stress leads to phosphorylation of IRS-1 at S³⁰⁷ and reduced Akt phosphorylation via JNK. In contrast, a study by Brown et al. [155] has shown that ER stress does not affect Akt phosphorylation at S⁴⁷³ and tyrosine IRS-1 phosphorylation. During ER stress, there is a reduction in the availability of matured insulin receptors and, at the same time, inhibition of phosphorylated Akt. It is important to note that the half-life of insulin receptors increases during ER stress [155].

ER stress and IRS exhibit a complex association, so it is necessary to determine if IRS affects ER stress in a feedback mechanism. The importance of IRS-1 or IRS-2, particularly under ER stress conditions, has not been thoroughly investigated in diabetes. Moreover, it remains unclear whether there is a phenotypic difference between IRS-1 and IRS-2 in diabetes during ER stress.

9. ER Stress and Nicotinamide Adenine Dinucleotide Phosphate (NAD(P)H) Oxidase

A transmembrane enzyme known as NAD(P)H oxidase (NOX) generates reactive oxygen species (ROS) as its major function. It consists of many subunits, among which are 2-activator subunits (NOXA1 and p67^{phox}), 7-NOX, 2-DUOX-specific maturation factors, and 2-organizers (p47^{phox} and NOXO1) [156–158]. Specifically, NADPH oxidase families such as NOX-1, NOX-2, NOX-3, NOX-4, and NOX-5 generate superoxide anion, as well as hydrogen peroxide as a downstream metabolite [156]. NOX oxidase has an electron transfer system consisting of the C terminal cytoplasmic region and the N terminal. NOX facilitates the movement of electrons from cytosolic NADPH via flavin adenine dinucleotide (FAD), which leads to superoxide anion (O₂⁻) production in the cytosol [34]. NOX, mitochondria, xanthine oxidase (OX), uncoupled eNOS, cytochrome P-450 oxygenase, and cyclooxygenase (COX) are some sources of ROS, as depicted in Figure 3.

NOX-2 is often colocalized with p22^{phox} in the membrane of intracellular vesicles, but the phosphorylation of p47^{phox} results in the translocation of p47^{phox}-p67^{phox} from the cytoplasm to the plasma membrane. The p47^{phox}/p67^{phox} interacts with p22^{phox}, followed by translocation of p40^{phox}; this sequence of events activates the NOX-2 [159, 160]. The activated NOX-2 results in the fusion of the vesicle to the plasma membrane releasing superoxide anion [156]. Some studies reported that NOX-2 and NOX-4 produce hydrogen peroxide (H₂O₂) only; however, other research has shown the production of superoxides (O₂⁻) as well [161]; the different results perhaps being attributable to the methods used or experimental conditions. NOX-2 has phagocytic and electron activities associated with phagosomes and proteases [162–164]. The expression and stimulation of NOX families (especially NOX-2) are associated with amplified Ca²⁺ release [156] and UPR stimulation [165]. The two lipids (cholesterol and 7-ketocholesterol) induce Ca²⁺ release and CHOP via

ER-receptors called the inositol-1,4,5-triphosphate receptor type-1 (IP3R-1) and Ca²⁺/calmodulin-dependent kinases-II (CaMK-II), respectively. The activation of these ER-receptors leads to ROS production, especially via the activation of NOX-2. The ROS produced by NOX-2 is thought to be sustained by CHOP and eIF2 α activation, serving as a feedback mechanism during ER stress [165]. The activation of ER stress through CHOP leads to more significant intracellular Ca²⁺ release and eventually causing more NOX-2 stimulation [165]. The ROS generated by NOX-2 is implicated in physiological processes such as cellular differentiation, proliferation, cytoskeletal organization, and migration [166].

The ER-localized NOX-4 has been found to lead to eNOS uncoupling and increased ROS [98]. Under prolonged ER stress, the JNK and ASK-1 signaling cascade is activated via IRE-1, leading to ER dysregulation and apoptosis [167]. The lack of NOX-4 hindered the transcription of many UPR markers, such as CHOP and Bax, associated with cell death initiation due to the activation and phosphorylation of JNK and ASK1, a signaling cascade of IRE1 activation [168]. The disulfide isomerase (PDI) enzyme on the ER is associated with NOX-4 and leads to reduced phosphorylation of Akt [169], which affects the survival of the cells. The physical association between p22^{phox} oxidase and PDI has been demonstrated in macrophages and neutrophils [170, 171]. The PDI-NOX-induced ROS downstream function remains unclear but may be linked to phagocytosis mediated by the ER [164]. ER-localized NOX-4 mediates oxidation; thus, inactivation of protein tyrosine phosphatase (PTB1B) during UPR, PTP1B may trigger IRE1-dependent signaling, an essential target for NOX-4 [172].

The generation of ROS is likely to happen during ER stress reaction and the orchestrated three-arm sensors. Also, an increase in ROS generation from the stimulated NOX may lead to diabetes. NOX-1, NOX-2, and NOX-4 oxidases are associated with ER stress redox signaling and metabolism for proapoptotic or prosurvival consequences. NOX-mediated ROS (hydrogen peroxide and superoxide) generation may stimulate other enzymatic systems to generate ROS [173, 174]. For instance, NOX generates ROS, which leads to oxidation of BH₄, a crucial factor for NO production in eNOS [175–178]. NOX has recently emerged as a critical oxidase mechanism that underlies oxidative stress in diabetic complications [179, 180] and diabetes [35]. Animal models of type 1 and type 2 diabetes have also registered NOX activation [181]. Prolonged activation of NOX has been associated with endothelial dysfunction in diabetes and diabetes. Notably, a few of the critical implications of NOX induction are stimulating several other oxidase mechanisms called NOX-dependent ROS production to maintain oxidative stress; these include ER stress, eNOS uncoupling, mitochondria, OX, cytochrome P-450 oxygenase, and COX. The functions of NOX families in association with ER stress are not fully elucidated.

ROS production is increased through the NOX family enzymes, primarily through the NOX-1, NOX-2, and NOX-4 isoforms under ER stress [182, 183]. NOX-1 [182], NOX-2 [165], and NOX-4 are the three NOX isoforms hitherto




FIGURE 3: The sources of superoxide anion. This figure shows how superoxide anion is obtained from various sources that generate hydrogen peroxide (H_2O_2) by superoxide dismutase (SOD). H_2O_2 can be catalyzed to H_2O . NO can react with superoxide anion to produce reactive nitrogen species (ONOO) that could be changed into $\text{NO}_2\cdot$, reacting with tyrosine residues to produce nitrotyrosine. These factors result in the reduced availability of NO and also lead to endothelial impediments.

confirmed to have been involved in ER stress [95, 165, 168, 184]. Camargo et al. [182] demonstrated that NOX-1 and NOX-4 are responsible for the irreversible oxidation and phosphorylation of PERK and IRE-1, respectively. NOX involves a different process in ER stress modulation, involving NOX-1-regulated PERK and NOX-4-regulated IRE-1. The plasma membrane is localized with NOX-1 and NOX-2, while the ER is localized with NOX-4, leading to increased ROS production in a cell.

During ER stress, hyperoxidation of the ER environment occurs, which initiates a UPR signaling cascade, resulting in the transfer of electrons from NADPH. These have a redox effect on ER and promote enhanced consumption of glutathione and thioredoxin reductase. Zeeshan et al. [185] identified that numerous external agents might stimulate intracellular ROS production, which decreases the antioxidant defense mechanism that can lead to an increase in oxidative stress and ER stress. Therefore, to achieve the therapeutic potential of targeting NOX isoforms and downstream oxidase systems to prevent and treat diabetes, innovative, reliable, and specific NOX isoform inhibitors are required. Also, the design of new approaches targeting other sources of ROS is crucial in diabetes.

10. Caveolin 1 (Cav-1) and eNOS

Caveolae are cell surface plasma membrane invaginations of 50 nm to 100 nm in diameter. They play a critical role in signal transduction, transcytosis, mechanosensation, mechanoprotection, maintenance of plasma membrane integrity, endocytosis, and lipid homeostasis [186]. They were once called simple membrane structures and are now regarded as more complex systems. The caveolae's primary membrane proteins contain caveolins that invaginate the cell membrane. The caveolins are divided into three types, i.e., caveolin-1, caveolin-2, and caveolin-3 (Cav-1/2/3) [187]. The protein

Cav-1 is oligomerized in the ER, after which it translocates to the Golgi body, where it may interact with cholesterol molecules before final release to the cellular membrane [188]. In most cell types, Cav-1 is expressed and crucial for the biosynthesis of caveolae. Cav-1 is usually expressed in endothelial cells, adipocytes, fibroblasts, and pneumocytes, along with Cav-2, which indicate they both play an essential function in the caveolar [189]. A total absence of caveolae results in loss of Cav-1 [190]. Other proteins have also been identified that play a crucial function in developing caveolae, for example, Cavin 1 to 4, pacsin2, and Eps 15 homology domain-containing protein 2 (EHD2) [191, 192].

eNOS [193], G-proteins [194], protein kinase A (PKA) [195], protein kinase C (PKC) [196], and many other receptors are identified in associated caveolae-enriched signaling molecules. Cav-1 has been proposed to bind and inhibit them via its caveolin scaffolding domain (CSD), a preserved amphipathic area for the development of caveolae and signaling cascade [194, 197, 198]. eNOS has received significant interest among these caveolae-located signaling molecules, thanks to its crucial vascular homeostasis effects [86, 199]. An investigation has shown that most eNOS dwell in endothelial cell caveolae [200, 201]. The findings underline the essential role of endothelial caveolae in managing eNOS activation, as depicted in Figure 4. eNOS has been linked with Cav-1 in nonactive endothelial cells, which hinders the calcium-calmodulin complex (CaM) from binding to eNOS [202]. The interaction between eNOS and Cav-1 prevents the electron transfer from NADPH to eNOS.

The M3-muscarinic acetylcholine receptor (M3) is a G protein-coupled receptor (GPCR) coupled to the Gq heterotrimeric protein through phospholipase C signaling cascades to produce cytosol calcium. For instance, ATP, bradykinin, endothelin-1, histamine, thrombin, ang II, and acetylcholine bind to M3 receptors to activate phospholipase C enzymes. The activation of these enzymes leads to the cleavage of




FIGURE 4: eNOS/Cav-1 interaction; it may be seen that eNOS is a homodimer limited to the Golgi apparatus and plasma membrane caveolae. In an inactive state, the caveolae protein is coupled to Cav-1, which reduces its action. Furthermore, when eNOS is phosphorylated by protein kinase C on Thr⁴⁹⁵, it inhibits contact with CaM. Inhibition of the enzyme can be achieved in a situation of oxidative stress caused in the aftermath of proline-rich tyrosine kinase 2- (PYK-2-) induced tyrosine phosphorylation of eNOS. Owing to cellular activation of eNOS, which is split from Cav-1, CaM can bind to the eNOS at Ser¹¹⁷⁷, thanks to Thr⁴⁹⁵ dephosphorylation, and produce EDRF.

phospholipid (phosphatidylinositol-4,5-bisphosphate) to produce inositol-1,4,5-trisphosphate (IP₃) and diacylglyceride. The IP₃ produced leads to the activation of inositol-1,4,5-trisphosphate receptors (IP₃Rs) localized on the ER. The increase in IP₃ produces a calcium signal within the endothelial cells, which takes a calcium wave, resulting in the release of calcium. The calcium-binding site, also known as the EF-hand domain, contains the N lobe and the C lobe calmodulin. The EF-hand domain is a polypeptide structure capable of detecting calcium. Calcium binds to the calmodulin to form a complex compound called the calcium-calmodulin complex (Ca²⁺-CaM). eNOS dissociates itself from Cav-1 and then merges with Ca²⁺-CaM. This allows the flow of electrons from NADPH and subsequently releases NO from eNOS [203, 204]. eNOS moves from the cell membrane to the Golgi complex, thanks to a higher cytosolic Ca²⁺ concentration, and is entirely activated. The production of NO leads to a reunion between eNOS and Cav-1, thereby halting the signaling cascade [205]. In vivo and in vitro studies have shown that eNOS can bind to Cav-1 and hinder NO synthesis [206, 207]. It is understood that overexpression of Cav-1 is linked to reduced acetylcholine-induced NO generation and vasodilation in patients with insulin resistance and type 2 diabetes [208]. Type 2 diabetic patients have shown downregulation of eNOS and Cav-1 expression in vascular endothelial cells [209]. However, it is unknown if there is either an increase or decrease in Cav-1 expression in diabetes, as seen in type II diabetes. A study by Rodrigues et al.

[210] has shown that caveolae dismantled with methyl- β -cyclodextrin ($m\beta cd$) treatment cause diminished relaxation by acetylcholine isolated aorta of the rat. Also, Al-brakati et al. [211] have demonstrated that caveolar disturbance results in decreased NO in femoral arteries. A study by Shamsaldeen et al. [212] has shown a decreased expression of eNOS and Cav-1 in the streptozotocin type I diabetic rat model. These disturbances in caveolae can decrease the levels of Cav-1 associated with eNOS, thereby undermining vascular function. The decrease in eNOS and Cav-1 expression in aortic endothelial cells from STZ-diabetic rats can inhibit PI3K/Akt cascades since wortmannin prevents eNOS and Cav-1 from moving to the cell membrane [213]. Insulin is known to stimulate a PI3K/Akt cascade, such that it allows eNOS and Cav-1 to move toward the cell membrane. Also, insulin triggers eNOS palmitoylation via Golgi palmitoyltransferase, enabling the acetylation of eNOS and Cav-1, which both of them translocate to the cell membrane [214]. The palmitoylation of eNOS and Cav-1 has been found to enhance the binding to the cell membrane nearly 10-fold, a process needed to maximize eNOS activity [215].

It is interesting to note that any metabolic disorders such as obesity, insulin resistance, diabetes, and diabetes may cause a change in the structural integrity of caveolae or Cav-1 concentration, leading to vascular dysfunction. Therefore, there is a need to determine the structural and molecular elements of how eNOS and Cav-1 influence each other's role in endothelial cells and how endothelial dysfunction

leads to diabetes because of their deficiency. Ultimately, further examination and clarification are likely to yield more insights into ways of reversing the process of restoring vascular homeostasis due to diabetes.

11. The Prospect of ER Stress and Associated Cellular Events

ER stress may lead to cellular death; it has been associated with the instigation and advancement of many diseases. The mitigation of ER stress and its residents has opened up new therapeutic frontiers for interventions in associated diseases [216]. Toth et al. [217] reported that ER stress and other cellular components play a vital role in survival and apoptosis, making them the best target for therapeutic intervention. The circumstances involving proapoptotic events in ER stress are associated with many pathways, including TRAF-2, ASK-1, CHOP, and JNK, thus developing a therapeutic approach that aims for a particular apoptotic path may not be sufficient to preserve cells [28]. Therefore, drug innovations require a holistic approach to comprehend the interrelationship between pathways involved in apoptosis due to ER stress.

The proapoptotic pathways and the arms of the UPR signaling pathways are extensively expressed during ER stress; therefore, averting their action could cause unprecedented adverse effects on the subject in question. Much research is desirable to elucidate the character of ER stress completely and the best therapeutic approaches to use within the connecting system. ER stress-associated molecular mechanisms and gene regulation that induce and advance cellular apoptosis are crucial for discovering novel molecular markers for future drug innovations in diabetes. Similarly, it is imperative to look at the contributions of noncanonical pathways in relation to diabetes during ER stress.

12. Conclusion

Endoplasmic reticulum homeostasis is critical in maintaining cellular functions. Sustained ER stress is associated with several metabolic disorders, including diabetes, mainly owing to the interplay of chronic hyperglycemia and hyperlipidemia. The ER stress response is now recognized as a converging molecular mechanism connecting insulin resistance, lipid metabolism distress, and oxidative stress to endothelial dysfunction, and cell death. ER stress also results in the accumulation of misfolded proteins countered by UPR associated with the activation of proinflammatory and proapoptotic pathways. Thus, understanding ER stress and its mechanisms, including homeostatic regulators such as the UPR, could help identify molecular targets for diabetes treatment.

Data Availability

This being a review article, no data was generated during the preparation of this manuscript.

Disclosure

This work was presented at the conference (<http://ff.unair.ac.id/conferences/icphs2020/eposter>).

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

Funding for this work was provided by the Ministry of High Education, Malaysia, via the Fundamental Research Grant Scheme (203/PPSP/6171215).

References

- [1] K. Ogurtsova, J. D. da Rocha Fernandes, Y. Huang et al., "IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040," *Diabetes Research and Clinical Practice*, vol. 128, pp. 40–50, 2017.
- [2] A. H. Mokdad, E. S. Ford, B. A. Bowman et al., "Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001," *Brief Report*, vol. 289, no. 1, pp. 2001–2004, 2003.
- [3] T. Vos, R. M. Barber, B. Bell et al., "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden Of Disease Study 2013," *The Lancet*, vol. 386, no. 9995, pp. 743–800, 2015.
- [4] A. Ghasemi and S. Jeddi, "Anti-obesity and anti-diabetic effects of nitrate and nitrite," *Nitric Oxide*, vol. 70, pp. 9–24, 2017.
- [5] Y. M. K. Farag and M. R. Gaballa, "Diabetes: an overview of a rising epidemic," *Nephrology Dialysis Transplantation*, vol. 26, no. 1, pp. 28–35, 2011.
- [6] G. Sesti, M. Federici, M. L. Hribal, D. Lauro, P. Sbraccia, and R. Lauro, "Defects of the insulin receptor substrate (IRS) system in human metabolic disorders," *FASEB Journal*, vol. 15, no. 12, pp. 2099–2111, 2001.
- [7] U. Smith, "Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance—is insulin resistance initiated in the adipose tissue?," *International Journal of Obesity*, vol. 26, no. 7, pp. 897–904, 2002.
- [8] L. Ellgaard, M. Molinari, and A. Helenius, "Setting the standards: quality control in the secretory pathway," *Science*, vol. 286, no. 5446, pp. 1882–1888, 1999.
- [9] P. Gual, Y. Le Marchand-Brustel, and J. F. Tanti, "Positive and negative regulation of insulin signaling through IRS-1 phosphorylation," *Biochimie*, vol. 87, no. 1, pp. 99–109, 2005.
- [10] C. J. Carlson, M. F. White, and C. M. Rondinone, "Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation," *Biochemical and Biophysical Research Communications*, vol. 316, no. 2, pp. 533–539, 2004.
- [11] F. Folli, C. Ronald Kahn, H. Hansen, J. L. Bouchie, and E. P. Feener, "Angiotensin II Inhibits insulin signaling in aortic smooth muscle cells at multiple levels: a potential role for serine phosphorylation in insulin/angiotensin II crosstalk," *Journal of Clinical Investigation*, vol. 100, no. 9, pp. 2158–2169, 1997.

- [12] P. Gual, T. Gonzalez, T. Grémeaux, R. Barrés, Y. Le Marchand-Brustel, and J. F. Tanti, "Hyperosmotic Stress Inhibits Insulin Receptor Substrate-1 Function by Distinct Mechanisms in 3T3-L1 Adipocytes," *Journal of Biological Chemistry*, vol. 278, no. 29, pp. 26550–26557, 2003.
- [13] H. Kanety, R. Feinstein, M. Z. Papa, R. Hemi, and A. Karasik, "Tumor Necrosis Factor α -induced Phosphorylation of Insulin Receptor Substrate-1 (IRS-1)," *Journal of Biological Chemistry*, vol. 270, no. 40, pp. 23780–23784, 1995.
- [14] C. Schmitz-Peiffer and J. P. Whitehead, "IRS-1 regulation in health and disease," *IUBMB Life*, vol. 55, no. 7, pp. 367–374, 2003.
- [15] F. Tremblay and A. Marette, "Amino acid and insulin signaling via the MTOR/P70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells," *Journal of Biological Chemistry*, vol. 276, no. 41, pp. 38052–38060, 2001.
- [16] J. J. Wilkes, A. Hevener, and J. Olefsky, "Chronic endothelin-1 treatment leads to insulin resistance in vivo," *Diabetes*, vol. 52, no. 8, pp. 1904–1909, 2003.
- [17] C. Yu, Y. Chen, G. W. Cline et al., "Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle," *Journal of Biological Chemistry*, vol. 277, no. 52, pp. 50230–50236, 2002.
- [18] O. M. Amen, S. D. Sarker, R. Ghildyal, and A. Arya, "Endoplasmic reticulum stress activates unfolded protein response signaling and mediates inflammation, obesity, and cardiac dysfunction: therapeutic and molecular approach," *Frontiers in Pharmacology*, vol. 10, pp. 1–21, 2019.
- [19] S. Serpillon, B. C. Floyd, R. S. Gupte et al., "Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 297, no. 1, pp. H153–H162, 2009.
- [20] J. Kang, Y. Sun, Y. Deng et al., "Autophagy-endoplasmic reticulum stress inhibition mechanism of superoxide dismutase in the formation of calcium oxalate kidney stones," *Bio-medicine & Pharmacotherapy*, vol. 121, p. 109649, 2020.
- [21] K. R. Porter, A. Claude, and E. F. Fullam, "A study of tissue culture cells by electron microscopy," *Journal of Experimental Medicine*, vol. 81, no. 3, pp. 233–246, 1945.
- [22] N. Borgese, M. Francolini, and E. Snapp, "NIH public access," *Cell Biology*, vol. 4, no. 18, pp. 358–364, 2006.
- [23] Y. Shibata, G. K. Voeltz, and T. A. Rapoport, "Rough sheets and smooth tubules," *Cell*, vol. 126, no. 3, pp. 435–439, 2006.
- [24] C. R. McMaster, "Lipid metabolism and vesicle trafficking: more than just greasing the transport machinery," *Biochemistry and Cell Biology*, vol. 79, no. 6, pp. 681–692, 2001.
- [25] S. H. Back and R. J. Kaufman, "Endoplasmic reticulum stress and type 2 diabetes," *Annual Review of Biochemistry*, vol. 81, no. 1, pp. 767–793, 2012.
- [26] A. Almanza, A. Carlesso, C. Chintha et al., "Endoplasmic reticulum stress signalling – from basic mechanisms to clinical applications," *FEBS Journal*, vol. 286, no. 2, pp. 241–278, 2019.
- [27] D. Ron and P. Walter, "Signal integration in the endoplasmic reticulum unfolded protein response," *Nature Reviews Molecular Cell Biology*, vol. 8, no. 7, pp. 519–529, 2007.
- [28] I. Kim, W. Xu, and J. C. Reed, "Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities," *Nature Reviews Drug Discovery*, vol. 7, no. 12, pp. 1013–1030, 2008.
- [29] T. Hayashi, R. Rizzuto, G. Hajnoczky, and S. Tsung-ping, "Mitochondria and the ER physically interact," *Trends in Cell Biology*, vol. 19, no. 2, pp. 81–88, 2009.
- [30] N. Budick-harmelin and M. Miaczynska, *Integration of the Endocytic System into the Network of Cellular Functions*, Springer International Publishing, 2018.
- [31] W. M. Henne, Z. Lu, Z. Balogi, C. Stefan, J. A. Pleiss, and S. D. Emr, "Mdm1/Snx13 is a novel ER-endolysosomal interorganellar tethering protein," *Journal of Cell Biology*, vol. 210, no. 4, pp. 541–551, 2015.
- [32] M. Hayashi-Nishino, N. Fujita, T. Noda, A. Yamaguchi, T. Yoshimori, and A. Yamamoto, "Electron tomography reveals the endoplasmic reticulum as a membrane source for autophagosome formation," *Autophagy*, vol. 6, no. 2, pp. 301–303, 2010.
- [33] T. Uemura, M. Yamamoto, A. Kametaka et al., "A cluster of thin tubular structures mediates transformation of the endoplasmic reticulum to autophagic isolation membrane," *Molecular and Cellular Biology*, vol. 34, no. 9, pp. 1695–1706, 2014.
- [34] B. Basha, S. M. Samuel, C. R. Triggle, and H. Ding, "Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress?," *Experimental Diabetes Research*, vol. 2012, 14 pages, 2012.
- [35] R. Villalobos-Labra, M. Subiabre, F. Toledo, F. Pardo, and L. Sobrevia, "Endoplasmic reticulum stress and development of insulin resistance in adipose, skeletal, liver, and foetoplacental tissue in diabetes," *Molecular Aspects of Medicine*, vol. 66, pp. 49–61, 2019.
- [36] K. Yamamoto, T. Sato, T. Matsui et al., "Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6 α and XBP1," *Developmental Cell*, vol. 13, no. 3, pp. 365–376, 2007.
- [37] G. Boden, P. Cheung, K. Kresge, C. Homko, B. Powers, and L. Ferrer, "Insulin resistance is associated with diminished endoplasmic reticulum stress responses in adipose tissue of healthy and diabetic subjects," *Diabetes*, vol. 63, no. 9, pp. 2977–2983, 2014.
- [38] C. G. Proud, "Regulation of protein synthesis by insulin," *Biochemical Society Transactions*, vol. 34, no. 2, pp. 213–216, 2006.
- [39] C. Adamopoulos, E. Farmaki, E. Spilioti, H. Kiaris, C. Piperi, and A. G. Papavassiliou, "Advanced glycation end-products induce endoplasmic reticulum stress in human aortic endothelial cells," *Clinical Chemistry and Laboratory Medicine*, vol. 52, no. 1, pp. 151–160, 2014.
- [40] S. Horke, I. Witte, P. Wilgenbus et al., "Protective effect of paraoxonase-2 against endoplasmic reticulum stress-induced apoptosis is lost upon disturbance of calcium homeostasis," *Biochemical Journal*, vol. 416, no. 3, pp. 395–405, 2008.
- [41] Y. Chen, J. J. Wang, J. Li et al., "Activating transcription factor 4 mediates hyperglycaemia-induced endothelial inflammation and retinal vascular leakage through activation of STAT3 in a mouse model of type 1 diabetes," *Diabetologia*, vol. 55, no. 9, pp. 2533–2545, 2012.
- [42] M. Liu, B. Spellberg, Q. T. Phan et al., "The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis

- in diabetic mice,” *Journal of Clinical Investigation*, vol. 120, no. 6, pp. 1914–1924, 2010.
- [43] M. Hu, F. Phan, O. Bourron, P. Ferré, and F. Foufelle, “Steatosis and NASH in type 2 diabetes,” *Biochimie*, vol. 143, pp. 37–41, 2017.
- [44] A. Bertolotti, X. Z. Wang, I. Novoa et al., “Increased sensitivity to dextran sodium sulfate colitis in IRE1 β -deficient mice,” *Journal of Clinical Investigation*, vol. 107, no. 5, pp. 585–593, 2001.
- [45] S. Basseri and R. C. Austin, “Endoplasmic reticulum stress and lipid metabolism: mechanisms and therapeutic potential,” *Biochemistry Research International*, vol. 2012, 13 pages, 2012.
- [46] E. B. Thorp, “The myocardial unfolded protein response during ischemic cardiovascular disease,” *Biochemistry Research International*, vol. 2012, 7 pages, 2012.
- [47] F. Luchetti, R. Crinelli, E. Cesarini et al., “Endothelial cells, Endoplasmic Reticulum Stress and Oxysterols,” *Redox Biology*, vol. 13, pp. 581–587, 2017.
- [48] T. Minamino and M. Kitakaze, “ER stress in cardiovascular disease,” *Journal of Molecular and Cellular Cardiology*, vol. 48, no. 6, pp. 1105–1110, 2010.
- [49] D. Han, A. G. Lerner, L. V. Walle et al., “IRE1 α Kinase Activation Modes Control Alternate Endoribonuclease Outputs to Determine Divergent Cell Fates,” *Cell*, vol. 138, no. 3, pp. 562–575, 2009.
- [50] J. Hollien, J. H. Lin, H. Li, N. Stevens, P. Walter, and J. S. Weissman, “Regulated Ire1-dependent decay of messenger RNAs in mammalian cells,” *Journal of Cell Biology*, vol. 186, no. 3, pp. 323–331, 2009.
- [51] K. Lei and R. J. Davis, “JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis,” *Proceedings of the National Academy of Sciences*, vol. 100, no. 5, pp. 2432–2437, 2003.
- [52] Y. Lei, S. Wang, B. Ren et al., “CHOP favors endoplasmic reticulum stress-induced apoptosis in hepatocellular carcinoma cells via inhibition of autophagy,” *PloS One*, vol. 12, no. 8, article e0183680, 2017.
- [53] E. C. Lumley, A. R. Osborn, J. E. Scott et al., “Moderate endoplasmic reticulum stress activates a PERK and P38-dependent apoptosis,” *Cell Stress and Chaperones*, vol. 22, no. 1, pp. 43–54, 2017.
- [54] T. Thoudam, J. H. Jeon, C. M. Ha, and I. K. Lee, “Role of mitochondria-associated endoplasmic reticulum membrane in inflammation-mediated metabolic diseases,” *Mediators of Inflammation*, vol. 2016, 18 pages, 2016.
- [55] Z. Liu, Y. Lv, N. Zhao, G. Guan, and J. Wang, “Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate,” *Cell Death & Disease*, vol. 6, no. 7, p. e1822, 2015.
- [56] H. Elouil, M. Bensellam, Y. Guiot et al., “Acute nutrient regulation of the unfolded protein response and integrated stress response in cultured rat pancreatic islets,” *Diabetologia*, vol. 50, no. 7, pp. 1442–1452, 2007.
- [57] Z. Q. Hou, H. L. Li, L. Gao, P. Lin, J. J. Zhao, and G. W. Li, “Involvement of chronic stresses in rat islet and INS-1 cell glucotoxicity induced by intermittent high glucose,” *Molecular and Cellular Endocrinology*, vol. 291, no. 1–2, pp. 71–78, 2008.
- [58] E. Gomez, M. L. Powell, A. Bevington, and T. P. Herbert, “A decrease in cellular energy status stimulates PERK-dependent EIF2 α phosphorylation and regulates protein synthesis in pancreatic β -cells,” *Biochemical Journal*, vol. 410, no. 3, pp. 485–493, 2008.
- [59] K. Zhang and R. J. Kaufman, “Signaling the Unfolded Protein Response from the Endoplasmic Reticulum,” *Journal of Biological Chemistry*, vol. 279, no. 25, pp. 25935–25938, 2004.
- [60] K. Haze, T. Okada, H. Yoshida et al., “Identification of the G13 (CAMP-response-element-binding protein-related protein) gene product related to activating transcription factor 6 as a transcriptional activator of the mammalian unfolded protein response,” *Biochemical Journal*, vol. 355, no. 1, pp. 19–28, 2001.
- [61] K. Haze, H. Yoshida, H. Yanagi, T. Yura, and K. Mori, “Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress,” *Molecular Biology of the Cell*, vol. 10, no. 11, pp. 3787–3799, 1999.
- [62] C. Hetz and F. R. Papa, “The unfolded protein response and cell fate control,” *Molecular Cell*, vol. 69, no. 2, pp. 169–181, 2018.
- [63] J. R. Hassler, D. L. Scheuner, S. Wang et al., “The IRE1 α /XBP1s pathway is essential for the glucose response and protection of β cells,” *PLoS Biology*, vol. 13, article e1002277, 2015.
- [64] M. D. Shoulders, L. M. Ryno, J. C. Genereux et al., “Stress-Independent Activation of XBP1s and/or ATF6 Reveals Three Functionally Diverse ER Proteostasis Environments,” *Cell Reports*, vol. 3, no. 4, pp. 1279–1292, 2013.
- [65] J. Wu, D. T. Rutkowski, M. Dubois et al., “ATF6 α optimizes long-term endoplasmic reticulum function to protect cells from chronic stress,” *Developmental Cell*, vol. 13, no. 3, pp. 351–364, 2007.
- [66] R. Asada, S. Kanemoto, S. Kondo, A. Saito, and K. Imaizumi, “The signalling from endoplasmic reticulum-resident BZIP transcription factors involved in diverse cellular physiology,” *Journal of Biochemistry*, vol. 149, no. 5, pp. 507–518, 2011.
- [67] E. A. H. Sims, E. Danforth Jr., E. S. Horton, J. A. Glennon, L. B. Salans, and G. A. Bray, *Endocrine and Metabolic Effects of Experimental Obesity in Man*, vol. 10254, Academic Press, Inc., 1973.
- [68] S. E. Kahn, R. L. Hull, and K. M. Utzschneider, “Mechanisms linking obesity to insulin resistance and type 2 diabetes,” *Nature*, vol. 444, no. 7121, pp. 840–846, 2006.
- [69] U. S. Kumar, T. D. Kumar, A. V. Preethi et al., “Involvement of essential signaling cascades and analysis of gene networks in diabetes,” *Genes*, vol. 11, no. 11, article 1256, 2020.
- [70] M. Kaneko, K. Imaizumi, A. Saito et al., “ER stress and disease: toward prevention and treatment,” *Biological and Pharmaceutical Bulletin*, vol. 40, no. 9, pp. 1337–1343, 2017.
- [71] S. Bhuvaneshwari, B. Yogalakshmi, S. Sreeja, and C. V. Anuradha, “Astaxanthin reduces hepatic endoplasmic reticulum stress and nuclear factor- κ B-mediated inflammation in high fructose and high fat diet-fed mice,” *Cell Stress and Chaperones*, vol. 19, no. 2, pp. 183–191, 2014.
- [72] S. G. Fonseca, J. Gromada, and F. Urano, “Endoplasmic reticulum stress and pancreatic β -cell death,” *Trends in Endocrinology & Metabolism*, vol. 22, no. 7, pp. 266–274, 2011.
- [73] M. Carlström, F. J. Larsen, T. Nyström et al., “Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice,” *Proceedings of the National Academy of Sciences*, vol. 107, no. 41, pp. 17716–17720, 2010.

- [74] M. Kelm, "Nitric oxide metabolism and breakdown," *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, vol. 1411, no. 2–3, pp. 273–289, 1999.
- [75] A. Sakinis and A. Wennmlm, "Estimation of total rate of formation of nitric oxide in the rat," *Biochemical Journal*, vol. 330, no. 1, Part 1, pp. 527–532, 1998.
- [76] D. A. Wagner, D. S. Schultz, W. M. Deen, V. R. Young, and S. R. Tannenbaum, "Metabolic fate of an oral dose of 15N-labeled nitrate in humans: effect of diet supplementation with ascorbic acid," *Cancer Research*, vol. 43, no. 4, pp. 1921–1925, 1983.
- [77] A. Wickman, N. Klintland, L.-m. Gan, and A. Sakinis, "A technique to estimate the rate of whole body nitric oxide formation in conscious mice," *Nitric Oxide*, vol. 9, no. 2, pp. 77–85, 2003.
- [78] R. Rafikov, F. V. Fonseca, S. Kumar et al., "ENOS activation and NO function: structural motifs responsible for the post-translational control of endothelial nitric oxide synthase activity," *Journal of Endocrinology*, vol. 210, no. 3, pp. 271–284, 2011.
- [79] P. J. Andrew and B. Mayer, "Enzymatic function of nitric oxide synthases," *Cardiovascular Research*, vol. 43, no. 3, pp. 521–531, 1999.
- [80] D. J. Stuehr, "Mammalian nitric oxide synthases," *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, vol. 1411, no. 2–3, pp. 217–230, 1999.
- [81] K. Nishida, D. G. Harrison, J. P. Navas et al., "Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase," *Journal of Clinical Investigation*, vol. 90, no. 5, pp. 2092–2096, 1992.
- [82] M. Ohno, G. H. Gibbons, V. J. Dzau, and J. P. Cooke, "shear stress elevates endothelial cGMP. role of a potassium channel and G protein coupling," *Circulation*, vol. 88, no. 1, pp. 193–197, 1993.
- [83] Y. Zhao, P. M. Vanhoutte, and S. W. Leung, "Vascular nitric oxide: beyond ENOS," *Journal of Pharmacological Sciences*, vol. 129, no. 2, pp. 83–94, 2015.
- [84] K. Schilling, N. Opitz, A. Wiesenthal et al., "Translocation of endothelial nitric-oxide synthase involves a ternary complex with caveolin-1 and NOSTRIN," *Molecular Biology of the Cell*, vol. 17, no. 9, pp. 3870–3880, 2006.
- [85] K. Zimmermann, N. Opitz, J. Dedio, C. Renné, W. Müller-Esterl, and S. Oess, "NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase," *Proceedings of the National Academy of Sciences*, vol. 99, no. 26, pp. 17167–17172, 2002.
- [86] D. M. Dudzinski and T. Michel, "Life history of ENOS: partners and pathways," *Cardiovascular Research*, vol. 75, no. 2, pp. 247–260, 2007.
- [87] J. L. Balligand, O. Feron, and C. Dessy, "ENOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues," *Physiological Reviews*, vol. 89, no. 2, pp. 481–534, 2009.
- [88] M. S. Alkaitis and M. J. Crabtree, "Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling," *Current Heart Failure Reports*, vol. 9, no. 3, pp. 200–210, 2012.
- [89] E. Gonzalez, R. Kou, A. J. Lin, D. E. Golan, and T. Michel, "Subcellular Targeting and Agonist-induced Site-specific Phosphorylation of Endothelial Nitric-oxide Synthase," *Journal of Biological Chemistry*, vol. 277, no. 42, pp. 39554–39560, 2002.
- [90] B. Vanhaesebroeck, S. J. Leeyers, G. Panayotou, and M. D. Waterfield, "Phosphoinositide 3-kinases: a conserved family of signal transducers," *Trends in biochemical sciences*, vol. 22, no. 7, pp. 267–272, 1997.
- [91] J. Zhu, W. Song, L. Lin, and X. Fan, "Endothelial nitric oxide synthase: a potential therapeutic target for cerebrovascular diseases," *Molecular Brain*, vol. 9, no. 30, pp. 1–8, 2016.
- [92] R. M. Goetz, I. Morano, T. Calovini, R. Studer, and J. Holtz, "Increased expression of endothelial constitutive nitric oxide synthase in rat aorta during pregnancy," *Biochemical and Biophysical Research Communications*, vol. 205, no. 1, pp. 905–910, 1994.
- [93] J. K. Liao, J. J. Zulueta, F.-s. Yu, H.-b. Peng, C. G. Cote, and P. M. Hassoun, "Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen," *Journal of Clinical Investigation*, vol. 96, no. 6, pp. 2661–2666, 1995.
- [94] W. C. Sessa, K. Pritchard, N. Seyedi, J. Wang, and T. H. Hintze, "Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression," *Circulation Research*, vol. 74, no. 2, pp. 349–353, 1994.
- [95] C. A. Chen, L. J. Druhan, S. Varadharaj, Y. R. Chen, and J. L. Zweier, "Phosphorylation of Endothelial Nitric-oxide Synthase Regulates Superoxide Generation from the Enzyme," *Journal of Biological Chemistry*, vol. 283, no. 40, pp. 27038–27047, 2008.
- [96] N. Anilkumar, R. Weber, M. Zhang, A. Brewer, and A. M. Shah, "Nox4 and Nox2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 7, pp. 1347–1354, 2008.
- [97] S. M. Son, "Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes," *Diabetes and Metabolism Journal*, vol. 36, no. 3, pp. 190–198, 2012.
- [98] H.-y. Lee, H.-k. Kim, T.-h. Hoang, S. Yang, H.-r. Kim, and H.-j. Chae, "The correlation of IRE1 α oxidation with Nox4 activation in aging-associated vascular dysfunction," *Redox Biology*, vol. 37, article 101727, 2020.
- [99] S. Mustapha, M. Mohammed, I. Yunusa, A. H. G. Rasool, and S. S. Mokhtar, "Potential risks of endoplasmic reticulum stress on vasculopathy in diabetes," *Obesity Medicine*, vol. 19, article 100274, 2020.
- [100] Y. Dong, C. Fernandes, Y. Liu et al., "Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosis," *Diabetes and Vascular Disease Research*, vol. 14, no. 1, pp. 14–23, 2017.
- [101] Y. S. Lau, M. R. Mustafa, K. W. Choy et al., "3',4'-Dihydroxyflavonol ameliorates endoplasmic reticulum stress-induced apoptosis and endothelial dysfunction in mice," *Scientific Reports*, vol. 8, no. 1, pp. 1–10, 2018.
- [102] T. V. Fiorentino, A. Prioletta, P. Zuo, and F. Folli, "Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases," *Current Pharmaceutical Design*, vol. 19, no. 32, pp. 5695–5703, 2013.
- [103] P. Geraldine and G. L. King, "Activation of protein kinase C isoforms and its impact on diabetic complications," *Circulation Research*, vol. 106, no. 8, pp. 1319–1331, 2010.
- [104] Y. Liu, S. Lei, X. Gao et al., "PKC β inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular

- hypertrophy and dysfunction in rats with streptozotocin-induced diabetes," *Clinical Science*, vol. 122, no. 4, pp. 161–173, 2012.
- [105] Y. Maeno, Q. Li, K. Park et al., "Inhibition of Insulin Signaling in Endothelial Cells by Protein Kinase C-induced Phosphorylation of p85 Subunit of Phosphatidylinositol 3-Kinase (PI3K)," *Journal of Biological Chemistry*, vol. 287, no. 7, pp. 4518–4530, 2012.
- [106] S. S. Mokhtar, P. M. Vanhoutte, S. W. S. Leung, R. Suppian, M. I. Yusof, and A. H. G. Rasool, "Reduced nitric oxide-mediated relaxation and endothelial nitric oxide synthase expression in the tail arteries of streptozotocin-induced diabetic rats," *European Journal of Pharmacology*, vol. 773, pp. 78–84, 2016.
- [107] M. Sheikh-Ali, S. Sultan, A. R. Alamir, M. J. Haas, and A. D. Mooradian, "Hyperglycemia-induced endoplasmic reticulum stress in endothelial cells," *Nutrition*, vol. 26, no. 11–12, pp. 1146–1150, 2010.
- [108] J. Struck, N. G. Morgenthaler, and A. Bergmann, "Proteolytic processing pattern of the endothelin-1 precursor in vivo," *Peptides*, vol. 26, no. 12, pp. 2482–2486, 2005.
- [109] M. Yanagisawa, H. Kurihara, S. Kimura et al., "A novel potent vasoconstrictor peptide produced by vascular endothelial cells," *Nature*, vol. 332, pp. 411–415, 1988.
- [110] A. Malassin, L. Cronier, F. Mondon, T. M. Mignot, and F. Ferré, "localization and production of immunoreactive endothelin-1 in the trophoblast of human placenta," *Cell & Tissue Research*, vol. 271, no. 3, pp. 491–497, 1993.
- [111] S. Gasic, O. F. Wagner, H. Vierhapper, P. Nowotny, and W. Waldhausl, "Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide," *Journal of Cardiovascular Pharmacology*, vol. 19, no. 2, pp. 176–180, 1992.
- [112] F. Rodríguez-Pascual, O. Busnadiego, D. Lagares, and S. Lamas, "Role of endothelin in the cardiovascular system," *Pharmacological Research*, vol. 63, no. 6, pp. 463–472, 2011.
- [113] Y. Mazaki, T. Higashi, Y. Onodera et al., "Endothelin type B receptor interacts with the 78-KDa glucose-regulated protein," *FEBS Letters*, vol. 593, no. 6, pp. 644–651, 2019.
- [114] L. Rosanò, F. Spinella, and A. Bagnato, "Endothelin 1 in cancer: biological implications and therapeutic opportunities," *Nature Reviews Cancer*, vol. 13, no. 9, pp. 637–651, 2013.
- [115] F. L. Marasciulo, M. Montagnani, and M. A. Potenza, "Endothelin-1: the Yin and Yang on vascular function," *Current Medicinal Chemistry*, vol. 13, no. 14, pp. 1655–1665, 2006.
- [116] F. H. Nystrom and M. J. Quon, "Insulin signalling: metabolic pathways and mechanisms for specificity," *Cell Signal*, vol. 11, no. 8, pp. 563–574, 1999.
- [117] M. A. Potenza, F. L. Marasciulo, D. M. Chieppa et al., "Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production," *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 289, pp. H813–H822, 2005.
- [118] M. A. Potenza, F. L. Marasciulo, M. Tarquinio, M. J. Quon, and M. Montagnani, "Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance," *Diabetes*, vol. 55, no. 12, pp. 3594–3603, 2006.
- [119] M. A. Potenza, F. Addabbo, and M. Montagnani, "Vascular actions of insulin with implications for endothelial dysfunction," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 297, no. 3, pp. E568–E577, 2009.
- [120] S. M. C. Simeone, M. W. Li, P. Paradis, and E. L. Schiffrin, "Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium," *Physiol Genomics*, vol. 43, no. 3, pp. 148–160, 2011.
- [121] G. S. Hotamisligil, "Endoplasmic reticulum stress and the inflammatory basis of metabolic disease," *Cell*, vol. 140, no. 6, pp. 900–917, 2010.
- [122] J. D. Malhotra and R. J. Kaufman, "Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?," *Antioxidants and Redox Signaling*, vol. 9, no. 12, pp. 2277–2294, 2007.
- [123] M. Ni and A. S. Lee, "ER chaperones in mammalian development and human diseases," *FEBS Letters*, vol. 581, no. 19, pp. 3641–3651, 2007.
- [124] M. O. R. Mian, N. Idris-Khodja, M. W. Li et al., "Preservation of endothelium-dependent relaxation in atherosclerotic mice with endothelium-restricted endothelin-1 overexpression," *Journal of Pharmacology and Experimental Therapeutics*, vol. 347, no. 1, pp. 30–37, 2013.
- [125] A. Jain, M. Olovsson, G. J. Burton, and H. W. Yung, "Endothelin-1 Induces Endoplasmic Reticulum Stress by Activating the PLC-IP₃ Pathway: Implications for Placental Pathophysiology in Preeclampsia," *American Journal of Pathology*, vol. 180, no. 6, pp. 2309–2320, 2012.
- [126] J. Wang, T. Takeuchi, S. Tanaka et al., "A mutation in the insulin 2 gene induces diabetes with severe pancreatic β -cell dysfunction in the moody mouse," *The Journal of clinical investigation*, vol. 103, pp. 27–37, 1999.
- [127] J. G. Schneider, N. Tilly, T. Hierl et al., "Elevated plasma endothelin-1 levels in diabetes mellitus," *American Journal of Hypertension*, vol. 15, no. 11, pp. 967–972, 2002.
- [128] B. G. Seligman, A. Biolo, C. A. Polanczyk, J. L. Gross, and N. Clausell, "Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia," *Diabetes*, vol. 23, pp. 1395–1400, 2000.
- [129] S. A. White, L. S. Zhang, D. J. Pasula, H. Yu, and C. Yang, "Bax and Bak jointly control survival and dampen the early unfolded protein response in pancreatic β -cells under glucolipotoxic stress," *Scientific Reports*, vol. 10, no. 1, pp. 1–12, 2020.
- [130] K. D. Capps and M. F. White, "Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2," *Diabetologia*, vol. 55, no. 10, pp. 2565–2582, 2012.
- [131] R. A. DeFronzo and D. Tripathy, "Skeletal muscle insulin resistance is the primary defect in type 2 diabetes," *Diabetes Care*, vol. 32, Supplement 2, pp. S157–S163, 2009.
- [132] H. K. R. Karlsson and J. R. Zierath, "Insulin signaling and glucose transport in insulin resistant human skeletal muscle," *Cell Biochemistry and Biophysics*, vol. 48, no. 2-3, pp. 103–113, 2007.
- [133] V. T. Samuel and G. I. Shulman, "Mechanisms for insulin resistance: common threads and missing links," *Cell*, vol. 148, no. 5, pp. 852–871, 2012.

- [134] M. F. White, "Mechanisms of Insulin Action," in *Atlas of Diabetes*, J. Skyler, Ed., pp. 19–38, Springer, 2012.
- [135] D. H. Bedinger and S. H. Adams, "Metabolic, anabolic, and mitogenic insulin responses: A tissue-specific perspective for insulin receptor activators," *Molecular and Cellular Endocrinology*, vol. 415, pp. 143–156, 2015.
- [136] S. M. Blattler, J. T. Cunningham, F. Verdeguer et al., "Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling," *Cell Metabolism*, vol. 15, no. 4, pp. 505–517, 2012.
- [137] B. A. Ersoy, A. Tarun, K. D. Aquino et al., "Phosphatidylcholine transfer protein interacts with thioesterase superfamily member 2 to attenuate insulin signaling," *Science Signaling*, vol. 6, p. ra64, 2014.
- [138] H. Zhu, N. Shyh-Chang, A. V. Segrè et al., "The Lin28/Let-7 axis regulates glucose metabolism," *Cell*, vol. 147, pp. 81–94, 2011.
- [139] R. Song, W. Peng, Y. Zhang et al., "Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders," *Nature*, vol. 494, no. 7437, pp. 375–379, 2013.
- [140] P. P. Hsu, S. A. Kang, J. Rameseder et al., "The MTOR-regulated phosphoproteome reveals a mechanism of MTORC1-mediated inhibition of growth factor signaling," *Science*, vol. 332, no. 6035, pp. 1317–1322, 2011.
- [141] F. Scheufele, B. Wolf, M. Kruse et al., "Evidence for a regulatory role of Cullin-RING E3 ubiquitin ligase 7 in insulin signaling," *Cellular Signalling*, vol. 26, no. 2, pp. 233–239, 2014.
- [142] A. Gupta, C. S. Dey, and J. Chernoff, "PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance," *Molecular Biology of the Cell*, vol. 23, pp. 3882–3898, 2009.
- [143] C. Mandavia and J. R. Sowers, "Phosphoprotein phosphatase PP2A regulation of insulin receptor substrate 1 and insulin metabolic signaling," *Cardiorenal Medicine*, vol. 2, no. 4, pp. 308–313, 2012.
- [144] C. Weigert, M. Kron, H. Kalbacher et al., "Interplay and effects of temporal changes in the phosphorylation state of serine-302, -307, and -318 of insulin receptor substrate-1 on insulin action in skeletal muscle cells," *Molecular endocrinology*, vol. 22, no. 12, pp. 2729–2740, 2008.
- [145] J. Giraud, M. Haas, E. P. Feener et al., "Phosphorylation of Irs1 at SER-522 inhibits insulin signaling," *Molecular Endocrinology*, vol. 21, no. 9, pp. 2294–2302, 2007.
- [146] Z. Yi, P. Langlais, E. A. De Filippis et al., "Global assessment of regulation of phosphorylation of insulin receptor substrate-1 by insulin in vivo in human muscle," *Diabetes*, vol. 56, pp. 1508–1516, 2007.
- [147] L. Ozcan, A. S. Ergin, A. Lu et al., "Endoplasmic Reticulum Stress Plays a Central Role in Development of Leptin Resistance," *Cell Metabolism*, vol. 9, no. 1, pp. 35–51, 2009.
- [148] S. H. Um, F. Frigerio, and M. Watanabe, "Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity," *Nature*, vol. 431, pp. 200–205, 2004.
- [149] Y. Zick, "Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance," *Science's STKE*, vol. 2005, p. pe4, 2005.
- [150] K. D. Copps, N. J. Hancer, L. Opere-ado, W. Qiu, C. Walsh, and M. F. White, "Irs1 serine 307 promotes insulin sensitivity in mice," *Cell Metabolism*, vol. 11, pp. 84–92, 2009.
- [151] A. E. Mehran, N. M. Templeman, G. Stefano Brigidi et al., "Hyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production," *Cell Metabolism*, vol. 16, no. 6, pp. 723–737, 2012.
- [152] L. Liang, J. Chen, L. Zhan, X. Lu, X. Sun, and H. Sui, "Endoplasmic reticulum stress impairs insulin receptor signaling in the brains of obese rats," *PLoS One*, vol. 10, no. 5, p. e0126384, 2015.
- [153] G. Solinas and B. Becattini, "JNK at the crossroad of obesity, insulin resistance, and cell stress response," *Molecular Metabolism*, vol. 6, no. 2, pp. 174–184, 2017.
- [154] S. Vernia, J. Cavanagh-kyros, L. Garcia-haro et al., "Article the PPAR α -FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway," *Cell Metabolism*, vol. 20, no. 3, pp. 512–525, 2014.
- [155] M. Brown, S. Dainty, N. Strudwick et al., "Endoplasmic reticulum stress causes insulin resistance by inhibiting delivery of newly synthesized insulin receptors to the cell surface," *Molecular Biology of the Cell*, vol. 31, no. 23, pp. 2597–2629, 2020.
- [156] K. Bedard and K.-h. Krause, "The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology," *Physiological Reviews*, vol. 87, no. 1, pp. 245–313, 2007.
- [157] X. Tang, Y. X. Luo, H. Z. Chen, and D. P. Liu, "Mitochondria, endothelial cell function, and vascular diseases," *Frontiers in Physiology*, vol. 5, pp. 1–17, 2014.
- [158] Y. Tang, J. Long, and J. Liu, *Hyperglycemia-Associated Oxidative Stress Induces Autophagy: Involvement of the ROS-ERK1/JNK-P53 Pathway*, vol. 1, Elsevier Inc., 2014.
- [159] R. A. Clark, B. D. Volpp, K. G. Leidal, and W. M. Nauseef, "Two cytosolic components of the human neutrophil respiratory burst oxidase translocate to the plasma membrane during cell activation," *Journal of Clinical Investigation*, vol. 85, no. 3, pp. 714–721, 1990.
- [160] W. Nauseef, "Assembly of the phagocyte NADPH oxidase," *Histochemistry and Cell Biology*, vol. 122, no. 4, pp. 277–291, 2004.
- [161] C. X. C. Santos, N. Anilkumar, M. Zhang, A. C. Brewer, and A. M. Shah, "Redox signaling in cardiac myocytes," *Free Radical Biology and Medicine*, vol. 50, no. 7, pp. 777–793, 2011.
- [162] A. R. Mantegazza, A. Savina, L. Pe et al., "NADPH oxidase controls phagosomal PH and antigen cross-presentation in human dendritic cells," *Blood*, vol. 112, no. 12, pp. 4712–4722, 2008.
- [163] A. Savina, C. Jancic, S. Hugues et al., "NOX2 controls phagosomal PH to regulate antigen processing during cross-presentation by dendritic cells," *Cell*, vol. 126, no. 1, pp. 205–218, 2006.
- [164] B. S. Stolf, I. Smyrniak, L. R. Lopes et al., "Protein disulfide isomerase and host-pathogen interaction," *Scientific World Journal*, vol. 11, pp. 1749–1761, 2011.
- [165] G. Li, C. Scull, L. Ozcan, and I. Tabas, "NADPH oxidase links endoplasmic reticulum stress, oxidative stress, and PKR activation to induce apoptosis," *Journal of Cell Biology*, vol. 191, no. 6, pp. 1113–1125, 2010.
- [166] D. I. Brown and K. K. Griendling, "Regulation of signal transduction by reactive oxygen species in the cardiovascular system," *Circulation Research*, vol. 116, no. 3, pp. 531–549, 2015.
- [167] S. S. Cao and R. J. Kaufman, "Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease,"

- Antioxidants and Redox Signaling*, vol. 21, no. 3, pp. 396–413, 2014.
- [168] E. Pedruzzi, C. Guichard, V. Ollivier et al., “NAD (P) H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress and apoptosis in human aortic smooth muscle cells,” *Molecular and Cellular Biology*, vol. 24, no. 24, pp. 10703–10717, 2004.
- [169] M. Janiszewski, L. R. Lopes, A. O. Carmo et al., “Regulation of NAD(P)H Oxidase by Associated Protein Disulfide Isomerase in Vascular Smooth Muscle Cells,” *Journal of Biological Chemistry*, vol. 280, no. 49, pp. 40813–40819, 2005.
- [170] A. M. D. A. Paes, S. Veríssimo-Filho, L. L. Guimarães et al., “Protein disulfide isomerase redox-dependent association with p47 phox: evidence for an organizer role in leukocyte NADPH oxidase activation,” *Journal of Leukocyte Biology*, vol. 90, no. 4, pp. 799–810, 2011.
- [171] X. C. Santos, B. S. Stolf, P. V. A. Takemoto et al., “Protein disulfide isomerase (PDI) associates with NADPH oxidase and is required for phagocytosis of *Leishmania chagasi* promastigotes by macrophages,” *Journal of Leukocyte Biology*, vol. 86, no. 4, pp. 989–998, 2009.
- [172] K. Chen, M. T. Kirber, H. Xiao, Y. Yu, and J. F. Keaney Jr., “Regulation of ROS signal transduction by NADPH oxidase 4 localization,” *Journal of Cell Biology*, vol. 181, no. 7, pp. 1129–1139, 2008.
- [173] H. Cai, “Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences,” *Cardiovascular Research*, vol. 68, no. 1, pp. 26–36, 2005.
- [174] N. S. Zinkevich and D. D. Gutterman, “ROS-induced ROS release in vascular biology: redox-redox signaling,” *American journal of physiology-heart and circulatory physiology*, vol. 301, pp. H647–H653, 2011.
- [175] L. Gao, Y.-f. Pung, J. Zhang et al., “Septippterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 297, no. 1, pp. H331–H339, 2009.
- [176] Q. Li, J. Y. Youn, K. L. Siu, P. Murugesan, Y. Zhang, and H. Cai, “Knockout of dihydrofolate reductase in mice induces hypertension and abdominal aortic aneurysm via mitochondrial dysfunction,” *Redox Biology*, vol. 24, article 101185, 2019.
- [177] X. N. Miao, K. L. Siu, and H. Cai, “Nifedipine attenuation of abdominal aortic aneurysm in hypertensive and non-hypertensive mice: Mechanisms and implications,” *Journal of Molecular and Cellular Cardiology*, vol. 87, pp. 152–159, 2015.
- [178] K. L. Siu, Q. Li, Y. Zhang et al., “NOX isoforms in the development of abdominal aortic aneurysm,” *Redox Biology*, vol. 11, pp. 118–125, 2017.
- [179] A. M. Amanso and K. K. Griendling, “Differential roles of NADPH oxidases in vascular physiology and pathophysiology,” *Frontiers in Bioscience*, vol. 4, pp. 1044–1064, 2013.
- [180] A. Konior, A. Schramm, M. Czesnikiewicz-Guzik, and T. J. Guzik, “NADPH oxidases in vascular pathology,” *Antioxidants & Redox Signaling*, vol. 20, no. 17, pp. 2794–2814, 2014.
- [181] Y. Zhang, P. Murugesan, K. Huang, and H. Cai, “NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets,” *Nature Reviews Cardiology*, vol. 17, no. 3, pp. 170–194, 2020.
- [182] L. L. Camargo, A. P. Harvey, F. J. Rios et al., “Europe PMC funders group vascular Nox compartmentalization, protein hyperoxidation and ER stress response in hypertension,” *Hypertension*, vol. 72, no. 1, pp. 235–246, 2019.
- [183] C. X. C. Santos, A. A. Nabeebaccus, A. M. Shah, L. L. Camargo, S. V. Filho, and L. R. Lopes, “Endoplasmic reticulum stress and Nox-mediated reactive oxygen species signaling in the peripheral vasculature: Potential role in hypertension,” *Antioxidants & Redox Signaling*, vol. 20, no. 1, pp. 121–134, 2014.
- [184] R.-f. Wu, Z. Ma, Z. Liu, and L. S. Terada, “Nox4-derived H₂O₂ mediates endoplasmic reticulum signaling through local ras activation,” *Molecular and cellular biology*, vol. 30, no. 14, pp. 3553–3568, 2010.
- [185] H. M. Zeeshan, G. H. Lee, H. R. Kim, and H. J. Chae, “Endoplasmic reticulum stress and associated ROS,” *International Journal of Molecular Sciences*, vol. 17, no. 3, pp. 1–20, 2016.
- [186] E. Shvets, A. Ludwig, and B. J. Nichols, “News from the caves: update on the structure and function of caveolae,” *Current Opinion in Cell Biology*, vol. 29, pp. 99–106, 2014.
- [187] K. G. Rothberg, J. E. Heuser, W. C. Donzell, J. R. Glenney, and R. G. W. Anderson, “Caveolin, a protein component of caveolae membrane coats,” *Cell*, vol. 68, no. 4, pp. 673–682, 1992.
- [188] K. S. Song, Z. Tang, S. Li, and M. P. Lisanti, “Mutational Analysis of the Properties of Caveolin-1,” *Journal of Biological Chemistry*, vol. 272, no. 7, pp. 4398–4403, 1997.
- [189] P. E. Scherer, T. Okamoto, M. Chun, I. Nishimoto, H. F. Lodish, and M. P. Lisanti, “Identification, sequence, and expression of caveolin-2 defines a caveolin gene family,” *Proceedings of the National Academy of Sciences*, vol. 93, no. 1, pp. 131–135, 1996.
- [190] M. Drab, P. Verkade, M. Elger et al., “Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice,” *Science*, vol. 293, no. 5539, pp. 2449–2452, 2001.
- [191] M. M. Hill, M. Bastiani, R. Luetterforst et al., “PTRF-cavin, a conserved cytoplasmic protein required for caveola formation and function,” *Cell Metabolism*, vol. 8, pp. 113–124, 2008.
- [192] M. Stoeber, I. K. Stoeck, C. Hänni, C. K. E. Bleck, G. Balistreri, and A. Helenius, “Oligomers of the ATPase EHD2 confine caveolae to the plasma membrane through association with actin,” *The EMBO Journal*, vol. 31, no. 10, pp. 2350–2364, 2012.
- [193] P. Bernatchez, A. Sharma, P. M. Bauer, E. Marin, and W. C. Sessa, “A noninhibitory mutant of the caveolin-1 scaffolding domain enhances ENOS-derived NO synthesis and vasodilation in mice,” *Journal of Clinical Investigation*, vol. 121, no. 9, pp. 3747–3755, 2011.
- [194] S. Li, T. Okamoto, M. Chun et al., “Evidence for a Regulated Interaction between Heterotrimeric G Proteins and Caveolin,” *Journal of Biological Chemistry*, vol. 270, no. 26, pp. 15693–15701, 1995.
- [195] S. Bryant, T. E. Kimura, C. H. T. Kong et al., “Stimulation of I_{Ca} by basal PKA activity is facilitated by caveolin-3 in cardiac ventricular myocytes,” *Journal of Molecular and Cellular Cardiology*, vol. 68, pp. 47–55, 2014.
- [196] Y. Shakirova, J. Bonnevier, S. Albinsson et al., “Increased Rho activation and PKC-mediated smooth muscle contractility in the absence of caveolin-1,” *American Journal of Physiology-Cell Physiology*, vol. 291, pp. 1326–1335, 2006.
- [197] H. H. Patel and F. Murray, “G-protein-coupled receptor-signaling components in membrane raft and caveolae

- microdomains,” in *Handbook of Experimental Pharmacology*, vol. 186, pp. 167–179, Springer, 2008.
- [198] K. S. Song, S. Li, T. Okamoto, L. A. Quilliam, M. Sargiacomo, and M. P. Lisanti, “Co-purification and Direct Interaction of Ras with Caveolin, an Integral Membrane Protein of Caveolae Microdomains;,” *Journal of Biological Chemistry*, vol. 271, no. 16, pp. 9690–9697, 1996.
- [199] C. Mineo, H. Deguchi, J. H. Griffin, and P. W. Shaul, “Endothelial and antithrombotic actions of HDL,” *Cardiovascular Research*, vol. 70, pp. 1352–1364, 2006.
- [200] M. Reiner, W. Bloch, and K. Addicks, “Functional interaction of caveolin-1 and ENOS in myocardial capillary endothelium revealed by immunoelectron microscopy,” *Journal of Histochemistry & Cytochemistry*, vol. 49, no. 12, pp. 1605–1609, 2001.
- [201] G. Sowa, J. Liu, A. Papapetropoulos, M. Rex-haffner, T. E. Hughes, and W. C. Sessa, “Trafficking of Endothelial Nitric-oxide Synthase in Living Cells;,” *Journal of Biological Chemistry*, vol. 274, no. 32, pp. 22524–22531, 1999.
- [202] H. Ju, R. Zou, V. J. Venema, and R. C. Venema, “Direct Interaction of Endothelial Nitric-oxide Synthase and Caveolin-1 Inhibits Synthase Activity;,” *Journal of Biological Chemistry*, vol. 272, no. 30, pp. 18522–18525, 1997.
- [203] M. Bucci, J.-P. Gratton, R. D. Rudic et al., “_In vivo_ delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation,” *Nature Medicine*, vol. 6, no. 12, pp. 1362–1367, 2000.
- [204] G. Sowa, M. Pypaert, and W. C. Sessa, “Distinction between signaling mechanisms in lipid rafts vs. caveolae,” *Proceedings of the National Academy of Sciences*, vol. 98, no. 24, pp. 14072–14077, 2001.
- [205] S. D. S. Oliveira and R. D. Minshall, *Caveolin and Endothelial NO Signaling*, vol. 82 Elsevier Inc., 1st edition, 2018.
- [206] X. Gu, S. J. Fliesler, Y.-y. Zhao, W. B. Stallcup, A. W. Cohen, and M. H. Elliott, “Loss of Caveolin-1 Causes Blood-Retinal Barrier Breakdown, Venous Enlargement, and Mural Cell Alteration,” *The American Journal of Pathology*, vol. 184, no. 2, pp. 541–555, 2014.
- [207] S. Ray and J. H. R. Maunsell, “Different origins of gamma rhythm and high-gamma activity in macaque visual cortex,” *PLoS One*, vol. 8, article e58481, 2011.
- [208] L. Yue, J.-t. Bian, I. Grizelj et al., “Apolipoprotein E enhances endothelial-NO production by modulating caveolin 1 interaction with endothelial NO synthase,” *Hypertension*, vol. 60, pp. 1040–1046, 2012.
- [209] Z. Chen, S. D. S. Oliveira, A. M. Zimnicka et al., “Reciprocal regulation of ENOS and caveolin-1 functions in endothelial cells,” *Molecular Biology of the Cell*, vol. 29, no. 10, pp. 1190–1202, 2018.
- [210] G. J. Rodrigues, C. B. A. Restini, C. N. Lunardi, A. Neto, J. E. Moreira, and L. M. Bendhack, “Decreased number of caveolae in endothelial cells impairs the relaxation induced by acetylcholine in hypertensive rat aortas,” *European Journal of Pharmacology*, vol. 627, no. 1–3, pp. 251–257, 2010.
- [211] A. Y. Al-brakati, T. Kamishima, C. Dart, and J. M. Quayle, “Caveolar disruption causes contraction of rat femoral arteries via reduced basal NO release and subsequent closure of BKCa channels,” *PeerJ*, vol. 3, article e966, 2015.
- [212] Y. A. Shamsaldeen, L. A. Lione, and C. D. Benham, “Dysregulation of TRPV4, ENOS and caveolin-1 contribute to endothelial dysfunction in the streptozotocin rat model of diabetes,” *European Journal of Pharmacology*, vol. 888, p. 173441, 2020.
- [213] H. Wang, A. X. Wang, Z. Liu, W. Chai, and E. J. Barrett, “The trafficking/interaction of ENOS and caveolin-1,” *Molecular Endocrinology*, vol. 23, pp. 1613–1623, 2009.
- [214] C. Fernández-hernando, M. Fukata, P. N. Bernatchez et al., “Identification of golgi-localized acyl transferases that palmitoylate and regulate endothelial nitric oxide synthase,” *Journal of Cell Biology*, vol. 174, no. 3, pp. 369–377, 2006.
- [215] P. W. Shaul, E. J. Smart, L. J. Robinson et al., “Acylation Targets Endothelial Nitric-oxide Synthase to Plasmalemmal Caveolae,” *Journal of Biological Chemistry*, vol. 271, no. 11, pp. 6518–6522, 1996.
- [216] C. Zhang, S. He, Y. Li et al., “Bisoprolol protects myocardium cells against ischemia/reperfusion injury by attenuating unfolded protein response in rats,” *Scientific Reports*, vol. 7, no. 1, pp. 1–12, 2017.
- [217] A. Toth, P. Nickson, A. Mandl, M. Bannister, K. Toth, and P. Erhardt, “Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease,” *Cardiovascular and Haematological Disorder-Drug Target*, vol. 7, no. 3, pp. 205–218, 2007.